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Abstract 
 Dynamic variations in DNA methylation are known to play an important role in cancer 
development through modulation of gene expression. Here, were developed a mathematical 
structured model to identify patterns of differentially methylated genes (cDMGs), across 
different cancers types that can act as epigenetic diagnostic biomarkers.  
            A Working Pipeline (WP), designed in R language, was applied to 8 cancer cohorts 
from The Cancer Genome Atlas (TCGA) aiming to analyze DNA methylation and gene 
expression alterations occurring during normal to stage I carcinogenic transition. 
 WP has a principal component which was divided in four steps: 0. Clinical 
characterization of patients; 1. Identification of cDMGs; 2. Identification of genetic/epigenetic 
patterns across different cancer type; and 3. Identification of diagnostic predictors. 
Additionally, the WP had a second component containing two more complementary steps: 4. 
Identification of CpG probes that better predict gene expression and 5. HJ-Biplot approach to 
visualize genes or CpG probes and its association with sample distribution. Appling the 
principal component of the WP to TCGA cohorts, we identified 117 cDMGs in breast cancer, 
307 in colorectal cancer, 99 in head and neck cancer, 156 in kidney clear cell cancer, 106 in 
kidney papillary cancer, 349 in liver cancer, 180 in lung cancer and 25 in thyroid cancer. 
Analysis of patterns across these cancers revealed that the majority of cDMGs are cancer-
specific. Moreover, we found cDMGs to be good predictors of diagnosis. When considering 
specific biomarkers for each cancer, only 19, 153, 27, 93, 53, 72, 38 and 14 genes were found 
to be good diagnostic biomarkers in breast, colorectal, head and neck, kidneyR, kidneyP, liver, 
lung and thyroid cancers, respectively. 
 Therefore, we developed a novel working pipeline that allowed data sets analyses 
available worldwide. Validation of this mathematical model evidences that normal-tumor 
transition is not a conserved process event across different cancers type, but specific to the cell 
of origin.  
  
Keywords: cancer, DNA methylation, gene expression, diagnosis biomarker and 
computational analysis.  
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Resumo 
 O cancro é descrito como um grupo de doenças altamente complexas caracterizadas 
pelo crescimento anormal e descontrolado de células com a capacidade de invadir outros 
tecidos. A vasta maioria das células presentes no organismo adulto apresentam o genoma 
completo, altamente regulado, de forma, a manter os padrões de atividade específica para cada 
tecido. Assim, os mecanismos que regulam esta atividade são importantes objetos de estudo no 
desenvolvimento de cancro, nomeadamente, a metilação do DNA.  
 A metilação do DNA é um dos mecanismos epigenéticos mais estudados que ocorre 
pela adição de um grupo metil à sequência de DNA, modificando a função dos genes e 
influenciando a expressão genética.  
 O cancro é maior causa de morbilidade e mortalidade no mundo, contando com 18.1 
milhões de novos casos e 9.6 milhões de mortes. Salienta-se, que os cancros do pulmão, mama 
e colorretal apresentam a maior taxa de incidência. 
 A presente dissertação teve como principais objetivos 1) criar um procedimento de 
trabalho, 2) identificar genes diferencialmente metilados associados a cancro (cDMGs), 3) 
identificar padrões de expressão/metilação entre diferentes tipos cancros e 4) identificar 
preditores de diagnóstico. 
 Metodologicamente, foi criado um procedimento de trabalho que teve aplicação na 
análise do genoma completo das coortes do The Cancer Genome Atlas (TCGA). A análise 
enunciada utilizou dados de expressão genética (Illumina Hiseq) e metilação de DNA (Illumina 
HumanMethylation 450K array) para 8 coortes dos seguintes tipos de cancro: cancro da mama, 
cancro colorretal, cancro da cabeça e pescoço, cancro das células renais (cancro do rimR), 
cancro papilar do rim (cancro do rimP), cancro do fígado, cancro do pulmão e cancro da tiroide. 
Neste projeto, foram comparados dois grupos, tecido sólido adjacente e tumor primário em 
estadio I com 84 e 126 em cancro da mama, 21 e 54 em cancro colorretal, 20 e 27 em cancro 
da cabeça e pescoço, 24 e 155 em cancro do rimR, 23 e 167 em cancro do rimP, 41 e 171 em 
cancro do fígado, 21 e 245 em cancro do pulmão e 50 e 284 em cancro da tiroide, 
respetivamente. Os dados mencionados foram analisados através de linguagem de programação 
em R.  
 Considerando os objetivos propostos, verificou-se que o primeiro objetivo é a chave 
para os restantes. O procedimento de trabalho foi estruturado com base em duas componentes 
distintas. A componente principal apresentou 4 fases: Fase 0 – Caracterização dos cohorts; Fase 
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1 – Identificar genes diferencialmente metilados associados a cancro; Fase 2 – Identificar 
padrões genéticos/epigenéticos entre diferentes tipos de cancro e Fase 3 – Identificar preditores 
de diagnóstico. Entretanto, a componente complementar apresentou 2 fases: Fase 4 – Identificar 
sítios de metilação com maior impacto na expressão e Fase 5 – Representação multivariada 
utilizando HJ-Biplot para visualizar genes ou sítios de metilação e a sua associação com a 
distribuição das amostras. 
 Dentro da componente principal, a Fase 0 foi considerada opcional e teve como intuito 
caracterizar os pacientes da coorte utilizando as variáveis clínicas disponíveis para tal. As fases 
seguintes estiveram dependentes da existência de dados de expressão genética (Illumina HiSeq) 
e metilação de DNA (Illumina HumanMethylation 450K array), assim como, pacientes que 
apresentem ambas as amostras. Deste modo, ambas as bases de dados foram importadas no 
início da Fase 1, os genes e sítios de metilação foram sujeitos a um pré-processamento, seguido 
de um processo de testes inferenciais distribuídos por níveis. Após seleção de genes com 
diferenças significativas de expressão e sítios de metilação com diferenças significativas de 
metilação estabeleceu-se os pontos de corte (valor absoluto log2(Foldchange)>1.5 e valor 
absoluto Δβ>0.2). Assim, foram selecionados apenas genes e CpG com diferenças muito 
significativas com interesse de estudo. Posteriormente, o teste de correlação de Pearson avaliou 
a relação entre ambos e identificou os genes diferencialmente metilados associados a cancro. A 
Fase 2 procurou identificar padrões através da interseção das várias coortes. Por fim, a Fase 3 
identificou os bons preditores de diagnóstico. De forma a complementar a análise, a Fase 4 
utilizou os modelos lineares de regressão múltipla para identificar a metilação de sítios de 
metilação com maior impacto na expressão de gene. Entretanto, a Fase 5 procurou de forma 
multivariada identificar comportamentos de gene ou sítios de metilação com maior influência 
na distinção entre grupos e na distribuição das amostras. 
 Através do procedimento de trabalho estabelecido, foram identificados nas coortes 
mama, colorretal, cabeça e pescoço, rimR, rimP, fígado, pulmão e tiroide, diferenças na 
expressão de 117, 307, 99, 156, 106, 349, 180 e 25 genes (valor absoluto de log2(Foldchange) 
> 1,5 e p-value ajustado (FDR)<0.05) e diferencialmente metiladas 368, 924, 292, 299, 224, 
1453, 601 e 40 sítios de metilação (valor absoluto de Δβ>0,2 e p-value ajustado (FDR)<0.05), 
respetivamente, designados de cDMGs. Seguidamente, foi realizada uma análise de processo 
biológico que revelou a existência de enriquecimento de funções ligadas ao desenvolvimento e 
sistema nervoso. Entretanto, foi realizada uma análise anotação com objetivo de verificar quais 
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dos cDMGs nunca foram reportados em cancro. Esta análise sugere que nas coortes acima 
mencionadas 18, 36, 13, 18, 15, 48, 20 e 3 genes, respetivamente, nunca foram mencionados 
com cancro. Por outro lado, 62, 150, 28, 27, 20, 94, 100 e 6 genes, respetivamente, já foram 
mencionados no cancro específico. Entretanto, os restantes já foram mencionados em cancro, 
mas não no cancro específico. 
 De seguida, a intersecção dos genes ou sítios de metilação entre coortes mostrou que a 
maioria eram específicos para o tipo tumoral e apenas uma pequena quantidade deles tinham 
presença em mais de uma coorte. Assim, para as coortes da mama, colorretal, cabeça e pescoço, 
rimR, rimP, fígado, pulmão e tiroide, são específicos para a coorte 55, 202, 49, 100, 70, 240, 97 
e 18 genes, respetivamente, e 261, 782, 223, 244, 189, 1339, 449 e 35 sítios de metilação, 
respetivamente. Seguidamente, foi realizada uma análise de vias de sinalização utilizando a 
base de dados Reactome que mostrou a cascata RAF/MAP quinase (p-value=8.01e-05) está 
muito presente em cancro colorretal, assim como, as interações L1CAM (p-value=0.004208). 
Adicionalmente, a ativação do recetor GABA A (p-value=0.026896) está enriquecido em 
cancro da cabeça e pescoço, os recetores péptido-ligando (p-value=0.006942) e a metilação de 
DNA (p-value=0.024459) em cancro do pulmão. Finalmente, os nossos resultados sugerem que 
o desenvolvimento de cancro em estadios precoces apresenta características intrínsecas ao 
tecido de origem. 
 Por último, a análise de bons preditores de diagnóstico teve como objetivo identificar 
biomarcadores com capacidade de discriminar tecido normal e tumoral em estadios precoces. 
Os nossos resultados mostraram que nas coortes previamente mencionados existiram 45, 238, 
57, 142, 88, 126, 88 e 18 genes, respetivamente, juntamente com 340, 835, 286, 299, 200, 1129, 
595 e 38 sítios de metilação, respetivamente. Destes, 44, 153, 68, 173, 111, 261, 128 e 24, 
respetivamente pertenceram aos padrões específicos encontrados.  
 Concluindo, nós criamos um procedimento de trabalho capaz de analisar bases de dados 
de todo o mundo. Como vimos, este estudo mostrou que o procedimento permitiu identificar 
diferenças de metilação significativas em estadios precoces. Estas alterações na sua grande 
maioria são específicas da transição normal-tumoral evidenciando que este evento não é 
conservado entre tipos de cancro, sugerindo que cada tecido apresenta características únicas do 
tipo de célula de origem. 
Palavras-chave: cancro, metilação de DNA, expressão genética, biomarcador de diagnóstico 
e análise computacional. 
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1 CHAPTER 1 – INTRODUCTION 
 
 
 
1.1. Cancer 
 Organisms present highly differentiated and specialized tissues that allow them to 
perform their functions autonomously. Most cells of an adult organism have the complete 
genome, meaning that they present more information than is necessary for its functioning. 
Proliferative capacity is an intrinsic feature to cells, allowing the tissue to maintain its functions 
and characteristics. This constant maintenance involves the repair of damage as well as cell 
replacement when possible (Weinberg 2014). This key rule of regulation is the crucial feature 
for cancer development. 
 When normal and functional tissues lose their original characteristics for which they 
have been programmed, they become dangerous to the body. The altered cells have now access 
to genome information which they would not normally have. Hence, changes in the genome 
that are promoted by this cellular and functional instability allow the cells to acquire new 
abnormal phenotypes. Tissues with abnormal cells compromise their function and proliferate 
wildly forming an abnormal cell mass, and then the tumor (Weinberg 2014).  
 Cancer can be considered a set of highly complex diseases characterized by abnormal 
and uncontrolled cell growth that can proliferate and invade other tissues (Hanahan et al. 2000). 
It is characterized by extensive amounts of genetic mutations and chromosomal abnormalities. 
Recently, aberrant epigenetic modifications have been highlighted in cancer and, together with 
genetic alterations, they have been useful for understanding the complexity observed in 
neoplasms. Therefore, the cancer epigenome has contributed greatly to the understanding of the 
complexity and diversity of different types of cancer. Nevertheless, the characterization of the 
epigenetic events during the tumorigenesis remains unclear. 
 
 
1.1.1. Epidemiology 
 Cancer can be considered the disease of the century and it is a major cause of morbidity 
and mortality worldwide, accounting for about 18.1 million new cases and 9.6 million cancer-
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related deaths, in 2018 (Bray et al. 2018). Develop countries with more resources a higher 
incidence of cancer. However, since they provide better healthcare services in terms of 
screening, diagnosis and treatment, the mortality rates are lower in the developed countries than 
in less developed ones (Bray et al. 2018). Among top seven of cancers with the highest 
incidence worldwide are lung (11.6%), breast (11.6%), colorectal (10.2%), prostate (7.1%), 
stomach (5.7%), liver (4.7%) and Oesophagus (3.2%), represented in Figure 1.1A. Then, the 
top seven of most deadly cancers worldwide are lung (18.4%), colorectal (9.2%), liver (8.2%), 
stomach (8.2%), breast (6.6%), oesophagus (5.3%) and pancreas (4.5%), represented in Figure 
1.1B. Worldwide, lung cancer is the cancer with the highest incidence and mortality (Bray et 
al. 2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Although, Europe contains 9% of the world's population, it has 25% of the global cancer 
rate. Thus, the constant updating of European statistics becomes a strong ally in cancer 
planning. Moreover, in Europe, it is estimated 3.91 million new cases and 1.93 million deaths 
due to cancer in 2018 (Ferlay et al. 2018). 
 In 2018, in Portugal, from the total of 10 291 198 people, 58 199 people were diagnosed 
and 28 960 died with cancer (Anon n.d.). When we look at the incidence (Figure 1.2A), the 
Figure 1.1 – Worldwide cancer estimated incidence and mortality rates for both sexes of 2018. Pie 
charts illustrated the different cancer estimated incidence (A) and mortality (B) rates in the worldwide 
population for the year 2018. From GLOBOCAN 2018 (IARC). 
A 
B 
3 
 
seven most common cancers in both sexes are colorectal (17.6%), prostate (11.4%), breast 
(12%), lung (9.1%), stomach (5%), bladder (4%) and non-Hodgkin lymphomas (3.6%). When 
we look at mortality (Figure 1.2B), the seven most deadly cancers are colorectal (14.7%), lung 
(16.1%), stomach (7.9%), breast (6%) and prostate (6.5%), pancreas (6.5%) and liver (4.7%). 
In Portugal, colorectal cancer is the cancer with the highest incidence and mortality (Anon n.d.). 
 The exponential increase of cancer cases is due to population growth and aging, and the 
number of cases is estimated to increase up to more than 20 million per year in 2030 (Stewart, 
BWKP and Wild 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2. Hallmarks of cancer 
 Tumorigenesis results from the transformation of normal cells into transformed cells 
which have lost their original characteristics (Hanahan et al. 2000). This transformation is a 
multistep process characterized by five main histological states: hypertrophy, hyperplasia, 
metaplasia, dysplasia and neoplasia. First, hypertrophy is characterized essentially by the 
increase of cell size without increasing in number. Second, hyperplasia is characterized by an 
Figure 1.2 – Portugal cancer estimated incidence and mortality rates for both sexes of 2018. Pie 
charts illustrated the different cancer estimated incidence (A) and mortality (B) rates in the Portuguese 
population for the year 2018. From GLOBOCAN 2018 (IARC). 
A 
B 
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increased number of cells. Third, metaplasia contemplates cells from different lineages due to 
be a transition phase. Fourth, dysplasia reveals changes in the function and shape of cells due 
to tissue disorganization. Finally, neoplasia is characterized by uncontrolled growth and loss of 
function associated to invasion of adjacent tissues and metastasis. The cell mass formed is 
designated as tumor, however not all tumors reach a stage of neoplasia, termed cancer 
(Weinberg 2014). 
 In 2000, to characterize this transformation, Douglas Hanahan and Robert Weinberg 
proposed six key capabilities that cells acquire during the multistep process of tumor 
development which are necessary for the development of cancer (Figure 1.3A). These 
hallmarks include (Hanahan et al. 2000): sustaining proliferative signaling; evading growth 
suppressors; activating invasion and metastasis; enabling replicative immortality; inducing 
angiogenesis; and resisting cell death. 
 Although these hallmarks are attributed to cancer, there are five characteristics (all 
except invasion and metastasis) common to benign tumors (Lazebnik 2010). Importantly, we 
must consider that they were established aiming to create lines of investigation to combat the 
mechanisms underlying the ability of cancers to kill, as such these characteristics are called 
hallmarks of cancer and not hallmarks of tumor. The benign and malignant tumors are not 
highly related, since both types can be: 
- Developed in the same organ; 
- Arises from the same cellular type; 
- Presented the same size;  
- And have the same external influence and occur spontaneously. 
Therefore, this arises the need to know the mechanisms that are behind tumor malignancy 
(invasion and metastasis- Lazebnik 2010). 
 In 2011, Hanahan and Weinberg re-evaluated the hallmarks to improve the 
characterization of cancer (Hanahan & Weinberg 2011). Hence, there is an extension of two 
new emerging hallmarks - deregulating cellular energetics and avoiding immune destruction - 
and two characteristics that enable the acquisition of all the previous hallmark capabilities: 
tumor-promoting inflammation and genome instability and mutation (Hanahan & Weinberg 
2011; Figure1.3B). 
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1.1.3. Modification of signaling pathways 
 Over the last decades, the evolution of techniques has allowed to more effectively 
characterize the biology of cancer by identifying specific molecular patterns in solid tumors of 
various types (Ferté et al. 2010). These altered molecular pathways create the environment 
conducive to tumorigenesis. With the identification of participants of these circuits, there are 
new biomarkers that appears as potential biomarkers for clinical application (Ferté et al. 2010). 
 Although there are many potential new biomarkers, only a small amount is currently 
used. The idea that a single biomarker is the best way of diagnosis has been surpassed by the 
existence of a group of biomarkers which are most effective in the diagnosis (Ferté et al. 2010). 
Figure 1.3 – Hallmarks of cancer. (A) Illustration of the six first proposed hallmarks of cancer. (B) 
Recently proposed emerging hallmarks and enabling characteristics that contribute for tumorigenesis. 
From Hanahan et al, 2011. 
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Transmission of signals depends on the molecular circuits. In fact, a molecule responds 
intensely to specific chemicals in its microenvironment: it can adjust its metabolism or alter 
gene expression patterns. Responses to physiological stimuli are mainly coordinated by 
chemical signals. Steps of this process which transform the message into a normal physiological 
response is are termed signal transmission (Berg et al. 2008). All these circuits present the main 
stages:  
 1st Liberation of the first messenger - external stimulus from the external environment 
(Berg et al. 2008);  
 2nd Reception of the first messenger - since most molecules do not enter the cell. 
Membrane proteins work as receptors that bind to the signaling molecules and transfer the 
information to the inside of the cell, according to the stimulatory molecule. Membrane receptors 
involve the entire cell, presenting multiple extra- and / or intracellular domains. The functional 
mechanism of this signal reception is promoted by a shift in the conformation of receptor 
domains upon binding of the stimulator. Importantly, an extracellular binding site recognizes 
specifically the signaling molecule (Berg et al. 2008);  
 3rd Delivery of the message inside the cell by the second messenger. Within cells, other 
small molecules are important for retransmitting information from receptor-ligand complexes. 
These molecules vary in concentration in response to environmental signals (Berg et al. 2008). 
Some of the second important messengers are cyclic AMP, cyclic GMP, calcium ion, inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG). The use of this second messenger molecule 
has several implications. First, the signal can be amplified significantly. Only a small number 
of receptors can be active by direct binding of the signaling molecules, but each receptor 
molecule can activate many second messengers. Secondly, the second messengers are 
commonly free to diffuse through the cell and influence various processes. Thirdly, the use of 
second messengers common to many routes creates both opportunities and potential threats 
(Berg et al. 2008);  
 4th Activation of effectors that alter the physiological response. The result of the signal 
in the signaling pathway is to activate or inhibit pumps, enzymes, and gene transcription factors 
that directly control metabolic pathways, the activation of gene expression, and processes such 
as nerve transmission (Berg et al. 2008);  
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 5th Conclusion of the signal - after obtaining the physiological response to a signal, the 
signaling processes end, otherwise the cell loses its ability to respond to new signals (Berg et 
al. 2008). 
 Molecular circuits are strong allies in the development of cancer through changes in all 
phases of signal transmission. Despite external inhibition stimulus, the cell alters the levels of 
molecules that potentiate proliferation allowing that the cell remains alive as well as the 
interaction with the receptors. Furthermore, effectors which promote proliferation are often 
augmented or constitutively active whereas effectors responsible by growth inhibition are 
blocked and functionless. However, the proper response does not reach its destination, or it is 
not terminated by remaining active and leading to the abnormality. Thus, signal transduction 
pathways assume the most critical roles in cancer development and progression, from external 
stimulus to physiological response, leading to alterations in gene expression. 
 
 
1.1.4. Tumors arise from many specialized cell types 
 Human tumors are mostly of epithelial origin, being named carcinomas (Weinberg 
2014). The epithelium is a stratified structure and each lamina is constituted by cells whose 
function is to protect the organs against external aggressions. These structures line the walls of 
the cavities and channels and are separated from the conjunctive tissue by the basement 
membrane. This structure separates two types of tissue providing structural support (Weinberg 
2014). Carcinomas are from various types and locations since gastrointestinal tract epithelium, 
to the skin, mammary gland, pancreas, lung, liver, ovary, uterus, prostate, gallbladder and 
bladder. On the other hand, there are also sarcomas, hematopoietic malignancies and 
neuroectodermal tumors (Weinberg 2014). 
 Carcinomas have different embryonic origins and can be classified according to the 
germ layer where were originated. Endoderm carcinomas are the most common and are 
constituted by the epithelia of the lung, liver, gallbladder, pancreas, oesophagus or intestines. 
Carcinomas of the mesoderm are constituted, for example, by the epithelium of the ovary or 
kidney. Ectodermal carcinoma arises mainly from the skin (Weinberg 2014). 
 In terms of function, carcinomas can be classified as squamous carcinomas, when they 
occur in tissues which have protective functions, or adenocarcinomas when they affect 
secretory tissues. Some organs such as the lung may have both (Weinberg 2014). 
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 Importantly, the progression of the tumor allows to classify it into benign or malignant. 
The tumor may be aggressive or have a slow and harmless development (Weinberg 2014). 
 
 
1.2. Mechanisms of gene expression regulation 
Proteins expressed by the cell are codified in coding genes. However, deoxyribonucleic 
acid (DNA) is not the direct template for protein synthesis (Berg et al. 2008). A DNA sequence 
is copied by a class of RNA molecules called messenger RNA (mRNA). This process is 
composed for two steps, transcription and translation whether the gene is coding, or only by 
transcription, when the gene is non-coding and has regulatory functions. The most common 
flow of genetic information in normal cells is: DNA, RNA and Protein (Berg et al. 2008). 
The genome can be considered a large file which is regulated in a meticulous way to 
minimize the damage caused by mutations. Most genes are present in identical amounts in all 
cells, i.e., one copy per haploid cell and two copies per diploid cell. Importantly, the level of 
gene expression, indicated by the number of mRNA copies, can vary widely, ranging from no 
expression to hundreds of copies. Additionally, the expression levels of the same gene may still 
vary and tends to account for the cell response to microenvironmental stimuli (Berg et al. 2008). 
Many genes presented in eukaryotic cells are considered as housekeeping genes, since 
they are constitutively expressed at low levels in all cells, being essentially responsible for 
encoding metabolism enzymes or cellular components (Hartl 2014). The expression levels of 
the remaining genes differs according to the cell type or stage of the cell cycle, being regulated 
by the control of transcription (Hartl 2014). There are different mechanisms involved in the 
transcription regulation, and certainly several of them are still not known. From these, 
mechanisms linked to epigenetics have been extremely relevant in this area. 
 
1.2.1. Epigenetic modifications 
Epigenetic modifications are reversible and do not change the DNA sequence. Among 
these are histone post-translational modifications, DNA methylation and non-coding RNAs, 
especially miRNAs (Dawson & Kouzarides 2012). The epigenome is crucial for regulating the 
physiology and pathology characteristic of each cell type. The specific pattern of gene 
expression and cell phenotypes are controlled epigenetically by marking histones through 
chemical changes and DNA through methylation, as well as through mechanisms such as 
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incorporation of histone variants, transcription of non-coding RNAs, editing of RNA and three-
dimensional chromatin remodelling (Vogel & Lassmann 2014). 
First fundamental epigenetic event in our body is called genomic imprinting and occurs 
in early stages during the embryonic development. This process affects dozens of mammalian 
genes and results in the expression of these genes from only one of the two parental 
chromosomes. Inactivation of one of the gene alleles is regulated by epigenetic instructions, 
established in the parental germ cells (Reik & Walter 2001). However, the development of the 
cellular progenitors and later the cellular differentiation and specialization of the tissues 
presents a unique epigenome that allows each cell type to present different functions and 
characteristics (Chang & Bruneau 2012; Cedar & Bergman 2011; Bharathy N., Ling B.M.T. 
2013). 
Contrary to the genome, the epigenome is dynamic and can be modified, and therefore 
some epigenetic risk markers have the potential to be reversed (Figure 1.4). External factors 
such as drugs, diet or environmental exposure can cause epigenetic changes (Bishop & 
Ferguson 2015). Fundamental understanding of epigenetic events in cell regulation opens a new 
window for altering the transcriptional state of cells, leading to changes in tumorigenesis. 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Epigenetic modifications that promote risk and / or progression of cancer and some 
factors. The green represents factors that can be modified. In red are represented factors that cannot be 
modified, they are intrinsic to the individual. From: Bishop KS. et all, 2015.   
10 
 
1.2.1.1 Histone modifications 
Histone modifications have a key role in the regulation of chromatin structure through 
dynamic patterns that can make the chromatin more or less condensed. These post-translational 
modifications regulate chromatin by influencing the folding, positioning and organization of 
DNA, altering processes such as gene expression. The complexity of this mechanism lies not 
only in the pattern of histone modification, but above all in the three-dimensionality of the 
structures and their dynamics (Bannister & Kouzarides 2011). Many of these modifications are 
illustrated in Figure 1.5 and include histone methylation, acetylation, phosphorylation and 
ubiquitylation (Bannister & Kouzarides 2011; Dawson & Kouzarides 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alterations in histones can happen through changes directly in the dynamics of the 
chromatin or involving the binding of the effector molecules (Bannister & Kouzarides 2011; 
Dawson & Kouzarides 2012). In the first mechanism acetylation and phosphorylation, for 
example, alter the histone charge due to their negative charge, weakening condensation and 
promoting the accessibility of DNA to transcription factors. In the second mechanism, some 
histone modifications do not cause severe changes, however, factors that are associated with it 
Figure 1.5 – Histone modifications. The histone code is defined by the post-translational changes that 
occur in their tails. The most common changes are illustrated in the figure: acetylation (blue), 
methylation (red), phosphorylation (yellow) and ubiquitination (green). The number below represents 
the position of the corresponding amino acid. From: Portela A. et all, 2010.   
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can induce these changes, such as factors associated to chromatin due to their different domains 
(Bannister & Kouzarides 2011; Dawson & Kouzarides 2012). 
Tumorigenesis presents aberrant epigenetic landscapes with post-translational 
modifications that activate oncogenes or inactivate tumor suppressor genes. The most frequent 
described alterations are both acetylation and methylation (Dawson & Kouzarides 2012). 
Acetylation is associated with genetic transcription and promotes chromatin opening due to its 
negative charge, which weakens the condensation due to neutralization of the positive histone 
tail. The addition of the acetyl group is carried out by histone acetyltransferases (HATs), and 
its removal is catalyzed by histone deacetylases (HDACs) (Yoo & Jones 2006). On the other 
hand, histone methylation acts as either the activator or repressor of gene transcription. The 
addition of a methyl group is performed by histone methyltransferase enzyme (HMTs) and 
removed by histone demethylases (HDMs) (Kooistra & Helin 2012). 
 
 
1.2.1.2 DNA methylation 
 DNA methylation is one of the epigenetic mechanisms that occurs by adding a methyl 
(CH3) group to the DNA sequence, modifying the gene function and, consequently, affecting 
gene expression. The most well-known and characterized methylation process is the covalent 
methylation of the carbon 5 of the cytosine pyrimidine ring in cytosine-guanine (CG) pair, 
resulting in 5-methylcytosine (5-mC). 
Methylation is controlled in cells at different levels and the enzymatic reaction is 
performed by a family of enzymes called DNA methyltransferases (DNMTs). In mammals, 
DNMT1 is the more active enzyme, being responsible for restoring DNA post-replication 
methylation sites, called DNA methylation maintenance. DNMT2 exhibits reduced activity in 
this area with the remaining DNA methyltransferases in vitro (Hermann et al. 2003), but their 
deletion in embryonic stem cell studies has shown no effect on overall methylation, suggesting 
that the enzyme does not have a function important in the maintenance and regulation of DNA 
methylation patterns (Okano et al. 1998). DNMT3A and DNMT3B are responsible for the 
methylation of new sites through a process called “de novo” methylation (Laird 2003; Baubec 
et al. 2015).  
In the de novo process, the recruitment of DNMTs to the DNA sequences target is 
unclear (Klose & Bird 2006). However, there are three possibilities: DNMTs recognize the 
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specific site through motifs; recruitment of DNMTs may occur due to protein-protein contact 
with transcription repressors or other intervening agents; or the interference-mediated RNA 
(RNAi) system may target this process for specific targets (Hervouet et al. 2009; Ge et al. 2004; 
Klose & Bird 2006; Baubec et al. 2015). 
The most common and widespread methylation sequence recognition motif is “5'-CpG-
3'”. CpG dinucleotides are unevenly distributed throughout the human genome. Moreover, there 
are defective and highly enriched segments of these dinucleotides, called CpG islands (Laird 
2003). About 50% of genes contain CpG islands in the region of the promoter, which is usually 
hypomethylated and associated to the activation of gene expression. In contrast, the literature 
frequently reported that hypermethylation in the same region inhibits gene expression. This 
process can occur through two pathways of inhibition. Firstly, through the recruitment of 
transcription inhibitors, such as methyl-binding proteins (MBDs), which form part of a large 
complex including histone deacetylases (HDACs), through co-repressor molecules to silence 
transcription and modify the surrounding chromatin, promoting a link between DNA 
methylation and chromatin remodeling and modification. Secondly, by directly blocking the 
binding site of methylation-sensitive transcription factors (TFs), such as MYC (Yoo & Jones 
2006). Epigenetic dogma focuses on the hypermethylation associated with gene repression, 
while hypomethylation has been associated to gene activation. Importantly, studies have shown 
that hypermethylation may also be associated with the activation of gene expression (Castelo-
Branco et al. 2013; Chao et al. 2015). Furthermore, genes that follow this pattern plays a key 
role in cancer (Bert et al. 2013). 
 Alterations in enzymes responsible for maintaining the epigenetic homeostasis may 
promote the deregulation of gene expression and, consequently, lead to tumorigenesis. 
 
 
1.2.1.3 MicroRNAs (miRNAs) 
 Small non-coding RNAs (20-30 nucleotides) are associated to a family of proteins called 
Argonaute family proteins (AGO) and can be micro RNA (miRNA), siRNA and PIWI-
interacting RNA (piRNA). miRNAs are the most abundant ncRNAs with about 22 nucleotides 
and act as regulators of protein-coding (Ha & Kim 2014). 
 Genes which codify to miRNA are transcribed by RNA polymerase II (Pol II) from 
intronic zones encoding protein genes or from dedicated miRNA gene loci (Lin & Gregory 
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2015). Primary miRNAs (primiRNAs) after being capped, spliced and polyadenylated are 
cleaved by the Microprocessor composed by DROSHA, RNase III and its cofactor; critical 
region of the DiGeorge syndrome (DGCR8); and double stranded RNA (dsRNA) binding 
protein (Lin & Gregory 2015). However, the pre-miRNAs formed are sent to the cytoplasm and 
processed by DICER which is helped by TRBP (Lin & Gregory 2015). Subsequently, TRBP 
assists the binding of DICER to AGO proteins to form the silencing complex (miRISC) which 
recruits a mature miRNA and promotes the binding to its complementary mRNA leading to 
post-translational gene silencing or DNA degradation (Lin & Gregory 2015). miRNA is 
constituted by a recognition domain termed "miRNA seed" which has a length of 6 nucleotides, 
located from position 2 to 7 of the 5'end. Importantly, the majority of the human protein coding 
genes have at least one binding site showing the relevance of miRNAs in the regulation of gene 
expression (Ha & Kim 2014). 
 Although miRNAs have distinct functions (oncogenic and tumor suppressor), studies 
have shown that their expression in a tumor is decreased compared to the normal tissue. It was 
also found that DROSHA and DICER are decreased in some types of cancer (Lin & Gregory 
2015). 
 
 
1.3. Epigenetic biomarkers have potential diagnostic in cancer 
Tumorigenesis is associated with successive changes that can be used for diagnosis or 
prognosis. The great challenge is to catalog all these changes and to find common and distinct 
patterns that allow to characterize and classify neoplasms correctly. Although each cancer is 
unique, there are common features that may have potential for clinical application and make 
diagnosis increasingly early, reducing progression and mortality. Importantly, epigenetic 
modifications have the potential to be reversible and become good drug targets. 
Studies for characterization of DNA methylation that occurs in different types of cancer 
have emerged in recent years. Specifically, hypermethylation analysis of gene promoters in 
serum has been shown to be a useful tool for cancer diagnosis (Fujiwara et al. 2005). Epigenetic 
changes are associated with pathological conditions such as neurological diseases, autoimmune 
diseases and cancer. Global methylation patterns change with tumorigenesis, causing 
hypomethylation of CpG probes located in the gene body and hypermethylation of CpG probes 
located in the gene promoter (De Carvalho et al. 2012). Aberrant DNA methylation of CpG 
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islands is a shared feature of various neoplasms and it is frequently associated with repression 
of tumor suppressor genes (Fujiwara et al. 2005). Epigenetic modifications constitute an 
innovative cancer biomarker due to factors such as stability, frequency, reversibility and 
accessibility in body fluids. Studies have shown the potential of these markers and some of 
them have already been commercialized (Costa-Pinheiro et al. 2015; Nikolaidis et al. 2012; 
Kneip et al. 2011; Warren et al. 2011). 
Genome-wide analysis of gene expression and DNA methylation using multiple cohorts 
is useful to identify common or specific patterns between them. Some studies have recently 
emerged using this more comprehensive approach (Wang et al. 2016; Zhang et al. 2015; Wei 
et al. 2016; Aran et al. 2017; Moon & Nakai 2018). 
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2 CHAPTER 2 – AIMS 
 Databases available online allow to perform analysis based on the use of computational 
tools to explore a large scale of hypotheses, aiming to find new patterns and eventually new 
biomarkers to characterize the various types of cancer, for example. The Cancer Genome Atlas 
(TCGA) provides gene expression and DNA methylation data from samples collected from 
multiples cohorts, which were obtained through the same techniques. Discovery of DNA 
methylation patterns associated with changes in gene expression was the major focus for the 
present study. Therefore, in this dissertation project, we intend to: 
1. Create a working pipeline for genome-wide analysis; 
2. Identify cancer differentially methylated genes (cDMGs) in early stages; 
3. Identify genetic/epigenetic patterns across different cancer types; 
4. Identify epigenetic diagnostic biomarkers. 
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3 CHAPTER 3 – MATERIALS AND METHODS 
 
 
3.1. Bioinformatics principal resources 
3.1.1. TCGA – The Cancer Genome Atlas 
The Cancer Genome Atlas is a project that resulted from a collaboration between the 
National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). 
This publicly funded project has helped to generate comprehensive, multi-dimensional maps of 
the key genomic changes for 33 cancer cohorts (Tomczak et al. 2015). This large-scale project 
as brought together large amounts of genetic and epigenetic information that can be used by the 
cancer research community to improve prevention, diagnosis and treatment. This database is 
available to the community (https://cancergenome.nih.gov/) and presents a package in R 
software (TCGAbiolinks) that facilitates the selection and download of the study cohort 
information. This factor was decisive for the selection of the data we use. 
 
 
3.1.2. Programming R language 
R is a programming language within statistical and graphical computing. This open 
source software provides a wide range of statistical tools and graphics techniques that are 
characterized by being easily extensible (https://www.r-project.org/ ). On the other hand, 
Bioconductor is an open source open source software project that provides tools for the analysis 
and processing of high-throughput genomic data based on the program R language 
(http://www.bioconductor.org/ ). Available Bioconductor tool used in this study is the 
TCGAbiolinks core package (Anon n.d.). One of these very important tools is the TCGAbiolinks 
core package in this study. 
 
 
3.1.3. TCGAbiolinks Package 
TCGAbiolinks version 2.7.3 is an R/Bioconductor package that allows performing a 
bioinformatic analysis in a sequenced way (Colaprico et al. 2016). The main functions that we 
used to prepare the database are: GDCquery, GDCdonwload and GDCprepare. GDCquery 
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summarizes the information for the GDC sample, taking into account all additional information, 
such as data category, data type, platform and barcode; GDCdownload is a data transfer tool 
selected by GDCquery; GDCprepare imports the downloaded data and prepares it for R project  
(Colaprico et al. 2018). 
 
 
3.2. Data extraction and prepare 
3.2.1. Selection of samples 
Samples were selected separately for each TCGA cohort with the help of the GDCquery 
function of package TCGAbiolinks, mentioned above. We performed an intersection of the 
patient’s ID from both databases, DNA methylation and gene expression, and selected IDs of 
patients matched. Importantly, the result of two databases was select using GDCquery functions 
with different criterions (Figure 3.1). Firstly, for DNA methylation, unmodified data (legacy = 
True) of the Illumina Human Methylation 450k array platform (platform = Illumina Human 
Methylation 450) was selected for the matched patients above mentioned (barcode) from the 
specific cohort (project = cohort). Secondly, for gene expression, unmodified data (legacy = 
True) of the Illumina HiSeq platform (platform = Illumina Hiseq) was selected for the matched 
patients above mentioned (barcode) from the specific cohort (project = cohort) and only 
normalized results files (file.type = normalized_results) of the genetic expression quantification 
(data.type = Gene Expression Quantification) were selected. The samples were grouped 
according to their typology in normal solid tissue and primary solid tumor (Figure 3.1A, Figure 
3.1B). Since we considered early stages, the samples corresponding to stage I were collected 
from the total patient samples using the indicative clinical variable, pathological stage. 
Additionally, we characterized each type of cancer based directly on the online directory 
(https://xenabrowser.net/) and the IDs previously selected. 
 In summary, sample type differentiates the solid tissue normal and primary solid tumor 
for both databases resulting in four GDCquery that define the bases of DNA methylation and 
gene expression for different types of samples. However, of the 33 cohorts present in the TCGA, 
9 cohorts were selected considering the match between patients and a minimum number of 20 
samples per group. Of the selected cohorts, colon and rectal cancer were treated together given 
the similarity between them. 
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Figure 3.1 - Samples selection. (A) Solid tissue normal samples selection. (B) Primary solid tumor 
samples selection. DNA methylation samples are selected based on the following criteria: project that 
defines which cohort; legacy provides access to an unmodified copy of data; data.category is defined as 
DNA methylation; platform is given by Illumina Human Methylation 450; sample.type is set to Solid 
Tissue Normal; and the barcode defines the IDs for patients with both samples. However, gene 
expression samples are selected based on the criteria: project that defines the cohort; data.category is 
define like Gene Expression; legacy provides access to an unmodified copy of data; data.type is defined 
as Gene Expression quantification; platform is given by Illumina HiSeq; file.type selects 
normalized_results data; and experimental.strategy defines the purpose of the RNA-Seq study. 
Sample.type and barcode aggregate samples of patients by typology.   
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3.3. Characterization of cohorts 
 Additionally, were exported clinical variables for each type of cancer using an online 
repository (https://xenabrowser.net/ ) from IDs previously selected by TCGAbiolinks package 
to perform a descriptive analysis that characterized the patients. Some variables such as age, 
gender, race, pathologic T, pathologic M and pathologic N are present in all cohorts. 
 
 
 
3.3.1. Breast invasive carcinoma (TCGA-BRCA) 
 Breast invasive carcinoma was selected from the repository with 84 normal solid tissue 
patients and 126 primary tumor patients in stage I, both with samples for DNA methylation and 
gene expression. 
 In Table 3.1 are represented the characteristics of patients for this cohort: the patients 
are all female with mean age and standard deviation of 58±15 for normal and 60±13 for tumor. 
The predominant race in normal patients is white with approximately 93%, while in white tumor 
with approximately 75% of whites and 21% of blacks or African Americans. 
 Considering the histological type, we verified the high incidence of ductal infiltration 
carcinoma. Associated with this factor is the presence of estrogen, progesterone and HER2 
receptors. Many patients are positive for estrogen receptors with approximately 70% normal 
and 75% for tumor, progesterone receptor positive with approximately 60% for normal and 
67% for tumor, and finally, approximately 56% of the tumors are negative for HER2 (Table 
3.1). 
 Clinically, the patients were mostly not exposed to neoadjuvant therapy and about half 
of both groups were subjected to radiation. Tumor patients are classified mainly in T1, N0 and 
M0 (Table 3.1). 
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Table  3.1 – Characteristics of the patients from TCGA breast invasive carcinoma cohort. 
TCGA-BRCA 
Characteristics 
Solid Tissue Normal 
(n = 84) 
Primary Tumor 
(n = 126) 
Age Mean ± SD1 58 ± 15 60 ± 13 
Gender Female 84 (100%) 126 (100%) 
Race 
Asian 1 (01.19%) 3 (02.38%) 
Black or African American 4 (07.41%) 26 (20.63%) 
White 78 (92.86%) 95 (75.40%) 
Not reported 1 (01.19%) 2 (01.59%) 
Pathologic 
Stage 
Stage I 11 (13.10%) 126 (100%) 
Stage II 51 (60.71%) 0 
Stage III 20 (23.81%) 0 
Stage IV 1 (01.19%) 0 
Not Reported 1 (01.19%) 0 
Histological 
Type 
Infiltrating Ductal Carcinoma 68 (80.95%) 89 (70.63%) 
Infiltrating Lobular Carcinoma 4 (04.76%) 20 (15.87%) 
Medullary Carcinoma 2 (02.38%) 1 (00.79%) 
Metaplastic Carcinoma 0 1 (00.79%) 
Mixed Histology 9 (10.71%) 4 (03.17%) 
Mucinous Carcinoma 0 4 (03.17%) 
Other 1 (01.19%) 6 (04.76%) 
Not Reported 0 1 (00.79%) 
History of 
Neoadjuvant 
Treatment 
No 84 (100%) 125 (99.21%) 
Yes 0 1 (00.79%) 
Radiation 
Therapy 
No 26 (30.95%) 56 (44.44%) 
Yes 35 (41.67%) 60 (47.62%) 
Not Reported 23 (27.38%) 10 (07.94%) 
Estrogen 
Receptor 
Status 
No 13 (15.48%) 26 (20.63%) 
Yes 59 (70.24%) 95 (75.40%) 
Not Reported 12 (14.29%) 5 (03.97%) 
Progesterone 
Receptor 
Status 
No 21 (25.00%) 37 (29.37%) 
Yes 50 (59.52%) 84 (66.67%) 
Not Reported 13 (15.48%) 5 (03.97%) 
HER2 
Receptor 
Status 
No 0 70 (55.56%) 
Yes 0 5 (03.97%) 
Not Reported 0 51 (40.48%) 
Pathologic T 
T1 18 (21.43%) 126 (100%) 
T2 52 (61.90%) 0 
T3 9 (10.71%) 0 
T4 5 (05.95%) 0 
Pathologic N 
N0 31 (36.90%) 120 (95.24%) 
N1 37 (44.05%) 4 (03.17%) 
N2 9 (10.71%) 0 
N3 4 (04.76%) 0 
NX 3 (03.57%) 2 (01.59%) 
Pathologic M 
M0 78 (92.86%) 107 (84.92%) 
M1 1 (01.19%) 0 
MX 5 (05.95%) 19 (15.08%) 
1. Standard Deviation 
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3.3.2. Colorectal adenocarcinoma (TCGA-COADREAD) 
 Colorectal adenocarcinoma was selected from the repository with 21 normal solid tissue 
patients and 54 primary tumor patients in stage I, both with samples for methylation and 
expression. 
 In Table 3.2 are represented the characteristics of patients for this cohort: in normal 
patients, 22% are men and 17% are women, the mean age and standard deviation is 68±13. In 
tumor patients, 59% are men and 41% women, the mean age and standard deviation is 66±13. 
Both groups are mostly made up of white individuals. 
 Considering the histological type, we verified that 90% of the normal ones have samples 
of colon adenocarcinoma, whereas in the tumors 70% of colon adenocarcinoma and 19% of 
rectum adenocarcinoma. The most common anatomical subdivision in cancer development is 
cecum with 35% and colon sigmoid with 19% (Table 3.2). 
 Clinically, patients were mostly not exposed to neoadjuvant therapy or radiation. 57% 
of colorectal patients have a family history of polyps and are classified mainly in T2, N0 and 
M0 (Table 3.2). 
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Table  3.2 – Characteristics of the patients from TCGA colorectal adenocarcinoma cohort. 
TCGA-COADREAD 
Characteristics 
Solid Tissue Normal 
(n = 21) 
Primary Tumor 
(n = 54) 
Age Mean ± SD1 68 ± 13 66 ± 13 
Gender 
Female 9 (16.67%) 22 (40.74%) 
Male 12 (22.22%) 32 (59.26%) 
Race 
Asian 0 0  
Black or African American 3 (14.29%) 8 (14.81%) 
White 10 (47.62%) 41 (75.93%) 
Not reported 8 (38.10%) 5 (09.26%) 
Pathologic 
Stage 
Stage I 2 (09.52%) 54 (100%) 
Stage II 11 (52.38%) 0 
Stage III 3 (14.29%) 0 
Stage IV 5 (23.81%) 0 
Histological 
Type 
Colon Adenocarcinoma 19 (90.48%) 38 (70.37%) 
Colon Mucinous Adenocarcinoma 0 5 (09.26%) 
Rectal Adenocarcinoma 2 (09.52%) 10 (18.52%) 
Not reported 0 1 (01.85%) 
Anatomic 
Neoplasm 
Subdivision 
Ascending Colon 2 (09.52%) 6 (11.11%) 
Cecum 4 (19.05%) 19 (35.19%) 
Descending Colon 1 (04.76%) 2 (03.70%) 
Hepatic Flexure 2 (09.52%) 2 (03.70%) 
Rectosigmoid Junction 0 6 (11.11%) 
Rectum 2 (09.52%) 4 (07.41%) 
Sigmoid Colon 8 (38.10%) 10 (18.52%) 
Splenic Flexure 0 1 (01.85%) 
Transverse Colon 0 3 (05.56%) 
Not reported 2 (09.52%) 1 (01.85%) 
Lymphatic 
Invasion 
No 11 (52.38%) 42 (77.78%) 
Yes 7 (33.33%) 6 (11.11%) 
Not reported 3 (14.29%) 6 (11.11%) 
History of 
Colon Polyps 
No 6 (28.57%) 31 (57.41%) 
Yes 8 (38.10%) 13 (24.07%) 
Not reported 7 (33.33%) 10 (18.52%) 
History of 
Neoadjuvant 
Treatment 
No 21 (100%) 54 (100%) 
Yes 0 0 
Radiation 
Therapy 
No 16 (76.19%) 46 (85.19%) 
Yes 1 (04.76%) 0 
Not reported 4 (19.05%) 8 (14.81%) 
Pathologic T 
T1 0 8 (14.81%) 
T2 2 (09.52%) 45 (83.33%) 
T3 17 (80.95%) 0 
T4 2 (09.52%) 0 
Tis 0 1 (01.85%) 
Pathologic N 
N0 14 (66.67%) 54 (100%) 
N1 4 (19.05%) 0 
N2 3 (14.29%) 0 
Pathologic M 
M0 11 (52.38%) 45 (83.33%) 
M1 5 (23.81%) 0 
MX 4 (19.05%) 9 (16.67%) 
Not reported 1 (04.76%) 0 
1. Standard Deviation 
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3.3.3. Head and neck squamous cell carcinoma (TCGA-HNSC) 
 Head and neck squamous cell carcinoma was selected from the repository with 20 
normal solid tissue patients and 27 primary tumor patients in stage I, both with samples for 
methylation and expression.  
 In Table 3.3 are represented the characteristics of patients for this cohort: in normal 
patients, 15% are men and 5% are women, the mean age and standard deviation is 64±12. In 
tumor patients, 52% are men and 48% women, the mean age and standard deviation is 62±16. 
Both groups are mostly made up of white individuals. 
 Considering the histological type, we verified that 100% of the normal ones have 
samples of head and neck squamous cell carcinoma in the tumors 96%. The most common 
anatomical subdivision in cancer development is oral tongue with 56% (Table 3.3). 
 Clinically, patients were mostly not exposed to radiation and are classified mainly in 
T1, N0 and M0 (Table 3.3). 
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Table  3.3 – Characteristics of the patients from TCGA head and neck squamous cell carcinoma 
cohort. 
TCGA-HNSC 
Characteristics 
Solid Tissue Normal 
(n = 20) 
Primary Tumor 
(n = 27) 
Age Mean ± SD1 64 ± 12 62 ± 16 
Gender 
Female 5 (%) 13 (48.15%) 
Male 15 (%) 14 (51.85%) 
Race 
Asian 0  1 (03.70%) 
Black or African American 0 2 (07.41%) 
White 20 (100%) 23 (85.19%) 
Not reported 0 1 (03.70%) 
Pathologic Stage 
Stage I 0 27 (100%) 
Stage II 6 (30.00%) 0 
Stage III 4 (20.00%) 0 
Stage IV 10 (50.00%) 0 
Anatomic 
Neoplasm 
Subdivision 
Alveolar Ridge 0 1 (03.70%) 
Base of tongue 1 (05.00%) 0 
Floor of mouth 2 (10.00%) 1 (03.70%) 
Hard Palate 0 1 (03.70%) 
Larynx 5 (25.00%) 2 (07.41%) 
Lip 0 2 (07.41%) 
Oral Cavity 3 (15.00%) 1 (03.70%) 
Oral Tongue 9 (45.00%) 15 (55.56%) 
Oropharynx 0 1 (03.70%) 
Tonsil 0 3 (11.11%) 
Histological 
Type 
Head & Neck Squamous Cell Carcinoma 20 (100%) 26 (96.30%) 
Head & Neck Squamous Cell Carcinoma 
Basaloid Type 
0 1 (03.70%) 
Lymphovascular 
Invasion 
No 6 (30.00%) 16 (59.26%) 
Yes 4 (20.00%) 2 (07.41%) 
Not Reported 10 (50.00%) 9 (33.33%) 
Radiation 
Therapy 
No 5 (25.00%) 18 (66.67%) 
Yes 6 (30.00%) 8 (29.63%) 
Not Reported 9 (45.00%) 1 (03.70%) 
Pathologic T 
T1 0 27 (100%) 
T2 7 (35.00%) 0 
T3 6 (30.00%) 0 
T4 7 (35.00%) 0 
Pathologic N 
N0 7 (35.00%) 24 (88.89%) 
N1 2 (10.00%) 0 
N2 6 (30.00%) 0 
NX 5 (25.00%) 3 (11.11%) 
Pathologic M 
M0 0 12 (44.44%) 
MX 0 3 (11.11%) 
Not Reported 20 (100%) 12 (44.44%) 
1. Standard Deviation 
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3.3.4. Kidney renal clear cell carcinoma (TCGA-KIRC) 
 Kidney renal clear cell carcinoma was selected from the repository with 24 normal solid 
tissue patients and 155 primary tumor patients in stage I, both with samples for methylation and 
expression.  
 In Table 3.4 are represented the characteristics of patients for this cohort: in normal 
patients, 75% are men and 25% are women, the mean age and standard deviation is 67±13. In 
tumor patients, 57% are men and 43% women, the mean age and standard deviation is 60±13. 
The predominant race in normal patients is white with approximately 83%, while in white tumor 
with approximately 77% of whites and 23% of blacks or African Americans. 
 Considering the histological type, we verified that 100% of patients have samples of 
kidney clear cell renal carcinoma (Table 3.4). 
 Clinically, tumor patients were mostly not exposed to radiation and are classified mainly 
in T1, NX and M0 (Table 3.4). 
 
Table  3.4 – Characteristics of the patients from TCGA kidney renal clear cell carcinoma cohort. 
TCGA-KIRC 
Characteristics 
Solid Tissue Normal 
(n = 24) 
Primary Tumor 
(n = 155) 
Age Mean ± SD1 67 ± 13 60 ± 13 
Gender 
Female 6 (25.00%) 67 (43.23%) 
Male 18 (75.00%) 88 (56.78%) 
Race 
Asian 0 0 
Black or African American 1 (04.17%) 35 (22.58%) 
White 20 (83.33%) 120 (77.42%) 
Not reported 3 (12.50%) 0 
Pathologic 
Stage 
Stage I 1 (04.17%) 155 (100%) 
Stage II 8 (33.33%) 0 
Stage III 7 (29.17%) 0 
Stage IV 8 (33.33%) 0 
Histological 
Type 
Kidney Clear Cell Rel Carcinoma 24 (100%) 155 (100%) 
Radiation 
Therapy 
No 2 (08.33%) 71 (45.81%) 
Not Reported 22 (91.67%) 84 (54.19%) 
Pathologic T 
T1 3 (12.50%) 155 (100%) 
T2 10 (41.67%) 0 
T3 10 (41.67%) 0 
T4 1 (04.17%) 0 
Pathologic N 
N0 10 (41.67%) 59 (38.06%) 
NX 14 (58.33%) 96 (61.94%) 
Pathologic M 
M0 17 (70.83%) 131 (84.52%) 
M1 7 (29.17%) 0 
MX 0 22 (14.19%) 
Not Reported 0 2 (01.29%) 
1. Standard Deviatio 
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3.3.5. Kidney renal papillary cell carcinoma (TCGA-KIRP) 
 Kidney renal papillary cell carcinoma was selected from the repository with 23 normal 
solid tissue patients and 167 primary tumor patients in stage I, both with samples for 
methylation and expression. 
 In Table 3.5 are represented the characteristics of patients for this cohort: in normal 
patients, 65% are men and 35% are women, the mean age and standard deviation is 63±14. In 
tumor patients, 75% are men and 25% women, the mean age and standard deviation is 62±12. 
The predominant race in normal patients is white with approximately 74%, while in white tumor 
with approximately 70% of whites and 22% of blacks or African Americans. 
 Considering the histological type, we verified that 100% of patients have samples of 
kidney papillary cell renal carcinoma (Table 3.5). 
 Clinically, patients were mostly not exposed to neoadjuvant therapy or radiation. Tumor 
patients are classified mainly in T2, NX and MX (Table 3.5). 
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Table  3.5 – Characteristics of the patients from TCGA kidney papillary clear cell carcinoma 
cohort. 
TCGA-KIRP 
Characteristics 
Solid Tissue Normal 
(n = 23) 
Primary Tumor 
(n = 167) 
Age Mean ± SD1 63 ± 14 62 ± 12 
Gender 
Female 8 (34.78%) 42 (25.15%) 
Male 15 (65.22%) 125 (74.85%) 
Race 
American Indian or Alaska Native 0 2 (01.20%) 
Asian 0 3 (01.80%) 
Black or African American 3 (13.04%) 36 (21.56%) 
White 17 (73.91%) 117 (70.06%) 
Not reported 3 (13.04%) 9 (05.39%) 
Pathologic 
Stage 
Stage I 10 (43.48%) 167 (100%) 
Stage II 1 (04.35%) 0 
Stage III 9 (39.13%) 0 
Stage IV 3 (13.04%) 0 
Histological 
Type 
Kidney Papillary Rel Cell Carcinoma 23 (100%) 167 (100%) 
History of 
Neoadjuvant 
Treatment 
No 23 (100%) 167 (100%) 
Radiation 
Therapy 
No 0 125 (74.85%) 
Not Reported 23 (100%) 42 (25.15%) 
Pathologic T 
T1 10 (43.48%) 167 (100%) 
T2 1 (04.35%) 0 
T3 11 (47.83%) 0 
T4 1 (04.35%) 0 
Pathologic N 
N0 8 (34.78%) 26 (15.57%) 
N1 5 (21.74%) 0 
NX 10 (43.48%) 141 (84.43%) 
Pathologic M 
M0 16 (69.57%) 52 (31.14%) 
M1 2 (08.70%) 0 
MX 5 (21.74%) 112 (67.07%) 
Not Reported 0 3 (01.80%) 
1. Standard Deviation 
 
 
3.3.6. Liver hepatocelular carcinoma (TCGA-LIHC) 
 Liver hepatocellular carcinoma was selected from the repository with 41 normal solid 
tissue patients and 171 primary tumor patients in stage I, both with samples for methylation and 
expression. 
 In Table 3.6 are represented the characteristics of patients for this cohort: in normal 
patients, 56% are men and 44% are women, the mean age and standard deviation is 60±16. 
In tumor patients, 71% are men and 29% women, the mean age and standard deviation is 61±12.  
 The predominant race in normal patients is white with approximately 63%, while in 
tumor with approximately 46% of whites and 46% of Asian. 
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 Considering the histological type, we verified that 100% of the normal ones have 
samples of hepatocellular carcinoma and in the tumors 98% (Table 3.6). 
 Clinically, patients were mostly not exposed to neoadjuvant therapy or radiation. Tumor 
patients are classified mainly in T1, N0 and M0 (Table 3.6). 
 
Table  3.6 – Characteristics of the patients from TCGA liver hepatocellular carcinoma cohort. 
TCGA-LIHC 
Characteristics 
Solid Tissue Normal 
(n = 41) 
Primary Tumor 
(n = 171) 
Age Mean ± SD1 60 ± 16 61 ± 12 
Gender 
Female 18 (43.90%) 50 (29.24%) 
Male 23 (56.10%) 121 (70.76%) 
Race 
Asian 5 (12.20%) 79 (46.20%) 
Black or African American 7 (17.07%) 8 (04.68%) 
White 26 (63.41%) 78 (45.61%) 
Not reported 3 (07.32%) 6 (03.51%) 
Pathologic 
Stage 
Stage I 17 (41.46%) 171 (100%) 
Stage II 7 (17.07%) 0 
Stage III 7 (17.07%) 0 
Stage IV 1 (02.44%) 0 
Not Reported 9 (21.95%) 0 
Histological 
Type 
Fibrolamellar Carcinoma 0 2 (01.17%) 
Hepatocellular Carcinoma 41 (100%) 167 (97.66%) 
Hepatocholangial Carcinoma (Mixed) 0 2 (01.17%) 
History of 
Neoadjuvant 
Treatment 
No 41 (100%) 169 (98.83%) 
Yes 0 2 (01.17%) 
Radiation 
Therapy 
No 32 (78.05%) 157 (91.81%) 
Yes 2 (04.88%) 2 (01.17%) 
Not Reported 7 (17.07%) 12 (07.02%) 
Pathologic T 
T1 19 (46.34%) 170 (99.42%) 
T2 10 (24.39%) 0 
T3 9 (21.95%) 0 
T4 3 (07.32%) 0 
Not Reported 0 1 (00.58%) 
Pathologic N 
N0 25 (60.98%) 127 (74.27%) 
N1 1 (02.44%) 0 
NX 14 (34.15%) 44 (25.73%) 
Not Reported 1 (02.44%) 0 
Pathologic M 
M0 27 (65.85%) 124 (72.52%) 
M1 1 (02.44%) 0 
MX 13 (31.71%) 47 (27.49%) 
1. Standard Deviation 
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3.3.7. Lung adenocarcinoma (TCGA-LUAD) 
 Lung adenocarcinoma was selected from the repository with 21 normal solid tissue 
patients and 245 primary tumor patients in stage I, both with samples for methylation and 
expression. 
 In Table 3.7 are represented the characteristics of patients for this cohort: in normal 
patients, 67% are men and 33% are women, the mean age and standard deviation is 64±12. In 
tumor patients, 41% are men and 59% women, the mean age and standard deviation is 66±10. 
The predominant race in normal patients is white with approximately 86%, while in tumor with 
approximately 79% of whites and 10% of black or African Americans. 
 Considering the histological type, we verified that 76% of the normal ones have samples 
of “Not Otherwise Specified” and in the tumors 62%. The most common anatomical 
subdivision in cancer development is R-upper (upper right lung) with 39% (Table 3.7). 
 Clinically, patients were mostly not exposed to neoadjuvant therapy or radiation. When 
we look at the smoker's history indicator for tumor patients, 12% are "Current reformed smoker 
for < or = 15 years" and 13% "Current reformed smoker for > 15 years", 64% of which are 
unreported. Tumor patients are classified mainly in T1/T2, N0 and M0 (Table 3.7). 
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Table  3.7 – Characteristics of the patients from TCGA lung adenocarcinoma cohort. 
TCGA-LUAD 
Characteristics 
Solid Tissue Normal 
(n = 21) 
Primary Tumor 
(n = 245) 
Age Mean ± Standard Deviation 64 ± 12 66 ± 10 
Gender 
Female 7 (33.33%) 145 (59.18%) 
Male 14 (66.67%) 100 (40.82%) 
Race 
Asian 0 4 (01.63%) 
Black or African American 3 (14.29%) 25 (10.20%) 
White 18 (85.71%) 193 (78.78%) 
Not reported 0 23 (09.39%) 
Pathologic 
Stage 
Stage I 12 (57.14%) 245 (100%) 
Stage II 4 (19.05%) 0 
Stage III 4 (19.05%) 0 
Stage IV 1 (04.76%) 0 
Anatomic 
Neoplasm 
Subdivision 
Bronchial 0 1 (00.41%) 
L-Lower 3 (14.29%) 36 (14.69%) 
L-Upper 5 (23.81%) 61 (24.90%) 
Other 0 1 (00.41%) 
R-Lower 1 (04.76%) 39 (15.92%) 
R-Middle 0 9 (03.67%) 
R-Upper 10 (47.62%) 96 (39.18%) 
Not Reported 2 (09.52%) 2 (00.82%) 
Histological 
Type 
Lung Acir Adenocarcinoma 0 12 (04.90%) 
Lung Adenocarcinoma Mixed Subtype 2 (09.52%) 44 (17.96%) 
Lung Adenocarcinoma- Not Otherwise 
Specified (NOS) 
16 (76.19%) 152 (62.04%) 
Lung Bronchioloalveolar Carcinoma 
Mucinous 
0 5 (02.04%) 
Lung Bronchioloalveolar Carcinoma 
Nonmucinous 
0 13 (05.31%) 
Lung Micropapillary Adenocarcinoma 0 1 (00.41%) 
Lung Mucinous Adenocarcinoma 2 (09.52%) 1 (00.41%) 
Lung Papillary Adenocarcinoma 0 11 (04.49%) 
Lung Signet Ring Adenocarcinoma 0 1 (00.41%) 
Lung Solid Pattern Predomint 
Adenocarcinoma 
0 4 (01.63%) 
Mucinous (Colloid) Carcinoma 1 (04.76%) 1 (00.41%) 
History of 
Neoadjuvant 
Treatment 
No 20 (95.24%) 245 (100%) 
Yes 1 (04.76%) 0 
Radiation 
Therapy 
No 15 (71.43%) 212 (86.53%) 
Yes 4 (19.05%) 16 (06.53%) 
Not Reported 2 (09.52%) 17 (06.94%) 
Pathologic T 
T1 8 (38.10%) 120 (48.98%) 
T2 11 (52.38%) 125 (51.02%) 
T3 1 (04.76%) 0 
T4 1 (04.76%) 0 
Pathologic N 
N0 11 (52.38%) 239 (97.55%) 
N1 4 (19.05%) 0 
N2 4 (19.05%) 0 
NX 2 (09.52%) 6 (02.45%) 
Pathologic M 
M0 18 (85.71%) 158 (64.49%) 
M1 1 (04.76%) 0 
MX 1 (04.76%) 85 (34.69%) 
Not Reported 1 (04.76%) 2 
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3.3.8. Thyroid carcinoma (TCGA-THCA) 
 Thyroid carcinoma was selected from the repository with 50 normal solid tissue patients 
and 284 primary tumor patients in stage I, both with samples for methylation and expression. 
 In Table 3.8 are represented the characteristics of patients for this cohort: in normal 
patients, 28% are men and 72% are women, the mean age and standard deviation is 46±17. In 
tumor patients, 24% are men and 76% women, the mean age and standard deviation is 38±13. 
The predominant race in normal patients is white with approximately 76%, while in tumor with 
approximately 65% of whites and 12% of Asian. 
 Considering the histological type, we verified that 84% of the normal ones have samples 
of thyroid papillary carcinoma - classical/usual and in the tumors 75% (Table 3.8). 
 Clinically, patients were mostly exposed to radiation, but not neoadjuvant therapy. 
Tumor patients are classified mainly in T1, N0/N1 and M0/MX (Table 3.8). 
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Table  3.8 – Characteristics of the patients from TCGA thyroid carcinoma cohort. 
TCGA-THCA 
Characteristics 
Solid Tissue Normal 
(n = 50) 
Primary Tumor 
(n = 284) 
Age Mean ± SD1 46 ± 17 38 ± 13 
ºGender 
Female 36 (72.00%) 216 (76.06%) 
Male 14 (28.00%) 68 (23.94%) 
Race 
American Indian or Alaska Native 0 1 (00.35%) 
Asian 3 (06.00%) 35 (12.32%) 
Black or African American 5 (10.00%) 11 (03.87%) 
White 35 (76.00%) 185 (65.14%) 
Not reported 7 (14.00%) 52 (18.31%) 
Pathologic 
Stage 
Stage I 30 (60.00%) 284 (100%) 
Stage II 5 (10.00%) 0 
Stage III 12 (24.00%) 0 
Stage IV 3 (06.00%) 0 
Histological 
Type 
Thyroid Papillary Carcinoma - 
Classical/usual 
42 (84.00%) 212 (74.65%) 
Thyroid Papillary Carcinoma - Follicular  5 (10.00%) 56 (19.72%) 
Thyroid Papillary Carcinoma - Tall Cell  3 (06.00%) 10 (03.52%) 
Other, specify 0 6 (02.11%) 
History of 
Neoadjuvant 
Treatment 
No 49 (98.00%) 283 (99.65%) 
Yes 1 (02.00%) 1 (00.35%) 
Radiation 
Therapy 
No 14 (28.00%) 123 (43.31%) 
Yes 34 (68.00%) 155 (54.58%) 
Not Reported 2 (04.00%) 6 (02.11%) 
Pathologic T 
T1 9 (18.00%) 121 (42.61%) 
T2 17 (34.00%) 96 (33.80%) 
T3 21 (42.00%) 64 (22.54%) 
T4 3 (06.00%) 1 (00.35%) 
TX 0 2 (00.70%) 
Pathologic N 
N0 25 (50.00%) 139 (48.94%) 
N1 20 (40.00%) 114 (40.14%) 
NX 5 (10.00%) 31 (10.92%) 
Pathologic M 
M0 33 (66.00%) 33 (66.00%) 
M1 2 (04.00%) 2 (04.00%) 
MX 15 (30.00%) 15 (30.00%) 
1. Standard Deviation 
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3.4. Export and prepare databases 
Databases were exported using the GDCdownload function and prepared for use in R, 
with the GDCprepare function of TCGAbiolinks package (Colaprico et al. 2016). Databases of 
DNA methylation and gene expression for normal solid tissue (Figure 3.2A) and primary solid 
tumor (Figure 3.2B) were downloaded, considering the previous function. Files were imported 
into R and organized by data frames available for use in R software.  
Databases were also pre-processed excluding:  CpG sites non-named, genes not matched 
to methylation and missing data gene.  
This procedure was fundamental considering the work guidelines. 
 
 
 
 
 
 
 
 
 
 
 
3.4.1. Gene expression Database 
 Gene expression (data level 3) was obtained from the Illumina HiSeq 2000 sequencing 
platform of TCGA genome characterization center, in the University of North Carolina 
(Illumina 2010; Anon n.d.). This platform tool presents a high accuracy associated with an 
Figure 3.2 - Export and prepare solid tissue normal samples. (A) Download and prepare DNA 
methylation and gene expression for solid tissue normal samples. (B) Download and prepare DNA 
methylation and gene expression for primary tumor samples. Samples were downloaded in separate 
folders and imported for use in R. 
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unprecedented output data demonstrating a breakthrough in the user experience (Illumina 
2010). Its ability allows it to process 200 samples of gene expression in a single run by Next 
Generation Sequence (Illumina 2010). Dataset shows the gene-level transcription estimates in 
transformed RSEM normalized count (Li & Dewey 2011). RSEM provides accurate 
quantification of transcription for species with no sequenced genome. This user-friendly and 
precise software tool is useful for quantifying the abutment of RNA-Seq data transcripts (Li & 
Dewey 2011). Data were normalized with log(x+1) to linearize the relationship between 
expression and methylation (Silva et al. 2016) and presented normalized expression values for 
20502 genes.   
 
 
3.4.2. DNA methylation Database 
Methylation quantification was obtained from the Illumina Infinium 
HumanMethylation450 platform by Johns Hopkins - USC Epigenome Center (Cost 2012). This 
high-throughput, low cost tool features extensive genome coverage, including more than 
450,000 methylation sites per sample at single nucleotide resolution. Technical capacity is quite 
powerful, ensuring more than 98% of technical replicas with a simple working protocol (Cost 
2012). 
The workflow is simple without requiring PCR and need a sample amount as low as 
500ng. The HumanMethylation 450 Beadchip applies two different chemical assays: Infinium 
I and Infinium II, to improve the coverage of the analysis (Figure 3.3). However, the 
development of Infinium II allows the use of degenerate oligonucleotide probes for a single 
bead type, making CpG sites with three nucleotides of separation have no interference in the 
methylation analysis. Finally, when we look to sensitivity of tool is able to detect the Δβ value 
of 0.2 with a lower than 1% false positive rate (Cost 2012). 
 Each probe has a methylation value (β-value) ranging from 0 (hypomethylated) to 1 
(hypermethylated), that show the intensity ratio of the methylated (M) bead type according to 
the combined, methylated and unmethylated (U), locus intensity (β = M/(M+U)), recorded by 
GenomeStudio software (Illumina Inc 2010; Siegmund n.d.). The DNA methylation data files 
included information of signal intensities (raw and normalized), detection confidence, and 
calculated beta values for methylated (M) and unmethylated (U) probes (Tomczak et al. 2015). 
Data obtained presented values for 364643 probes. 
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3.4.3. Removal of outliers 
Outliers assume much greater or less discrepant values in relation to most of the 
observations made (Cousineau 2011). These observations may not reflect the reality of 
sampling and may lead to data distortion reflecting changes in the mean value and variance of 
data that have an impact on results. The variance reflects how far in general the values are from 
the expected value, which value reflects where the data of a distribution is concentrated. 
Importantly, statistical inference processes are based on many of these dispersion measures. 
The impact of these measures becomes greater when the sample is small or when the 
statistics are less robust (Cousineau 2011). Thus, it is imperative to carry out the analysis of the 
sample to reduce the impact of these values in the interpretation of the obtained results. 
Procedures for outlier’s analysis are diverse. They can be classified in univariate or multivariate 
fields (Aguinis et al. 2013). An outlier’s analysis was performed considering one of the 
Figure 3.3 – Infinium HumanMethylation 450. In the left side, Infinium HumanMethylation 450 
Beadchip with extensive coverage for more than 450 000 methylation sites. In the right side, Infinium I 
and Infinium II assays chemistry technologies to improve the coverage of the analysis. 
37 
 
univariate methods analysis, the boxplot method. For gene expression and DNA methylation 
were performed boxplot representation (Figure 3.4). Inferior and superior limit were Q1-1.5 
Inter Quartile Range (IQR) and Q3+1.5 IQR, respectively (Aguinis et al. 2013). and the points 
that lie outside this representation are replaced by NA (not applicable) and considered an outlier. 
This procedure was performed for both bases, DNA methylation and gene expression, by the 
function present in Figure 3.4. 
 
 
 
 
 
 
 
 
 
3.4.4. Duplicated cases 
 In databases dimension analysis, after extraction for R, was considered the fact that each 
patient had two samples. Slight discrepancies were taking account since, in some cohorts, 
existed more than one sample for primary tumor. In those situations, through ID patient, was 
considered the median value and created a single data frame resulting from duplicate cases 
(Figure 3.5). Median is a good central tendency measure since extreme values have already 
been removed (Manikandan 2011). 
 
Figure 3.4 - Remove outliers function. This function created in R considers the outliers based on the 
boxplot method, replacing these discrepant values by NA, that is, missing value. 
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3.5. Statistical analysis 
 Descriptive statistics were performed to characterize the cancer cohorts. Inferential 
statistical analysis was executed to capture populational significant results regarding gene 
expression and DNA methylation, discriminated by solid tissue normal and stage I primary 
tumor. Before any comparative analyses (normal vs tumor), was performed a normality test to 
verify normal distribution. Results were considered statistically significant when p-value< 0.05, 
assuming the False Discovery Rate (FDR) correction < 0.05. 
 
3.5.1. Shapiro–Wilk normality test 
Shapiro-Wilk test was used to test the normal distribution. This procedure is important 
since the interpretation and statistical inference procedures must to be sustained. Shapiro–Wilk 
normality test represents the most powerful test in order to attest distribution behaviour 
considering sample size effect (Razali & Wah 2011). Parametric or non-parametric procedures 
were conducted based on the Shapiro-Wilk test results. A p-value<0,05 lidded to the rejection 
Figure 3.5 - Duplicate cases function. This function identifies duplicate samples IDs and collects those 
data frames by performing median for be transformed into single data frame. 
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of the null hypothesis, a sample came from a normally distributed population (Shapiro & Wilk 
1965), and therefore we opted for a non-parametric tests version. 
 This test was performed using shapiro.test function available in stats R package. 
 
 
3.5.2. Levene test 
 Groups variance is a very important assumption in statistical procedures, especially 
when we are testing, equal means by groups. Therefore, we performed Levene's test for 
homogeneity of variance across two samples (Levene 1960). The Levene's test results 
determined if we opted for Welch test (unequal variances t-test), which is more reliable in this 
context, or for the Student´s t-test (equal variances t-test). 
 This test was performed using leveneTest function available in car R package. 
 
 
3.5.3. Unpaired two-sample statistical tests 
 Wilcoxon Rank Sum test (Wilcoxon 1945) or Mann Whitney U test, a non-parametric 
alternative to Student´s t-test was used to compare two unpaired samples. This test takes into 
account the ranking differences between the two samples, and tests if the distributions of both 
populations are equal, or if they were independently selected from populations with same 
distribution.  
Student´s t-test is a parametric test used for testing equal populational means, in the 
presence of independent samples normally distributed, and assuming similar variance of 
groups. For unequal variances of groups we performed the Welch test (Welch 1947).  
 These tests were performed using wilcox.test and t.test function available in stats R 
package. 
 
 
3.5.4. Correction of multiple testing  
 Multiple comparisons increase the probability of taking false positives. An approach to 
controlling the false discovery rate (FDR) was proposed by Benjamini & Hochberg. This 
approach takes in account the order of p-values, considering the minimum accumulative to 
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verify the criteria   miq
m
i
p i ,...,1, 





 (Benjamini & Hochberg 1995). This condition provides 
a new set of p-values, which compared to the significance associated with the test and verified 
the previous criteria can be actualized.  
This correction was performed using p.adjust function available in stats R package. 
 
 
3.5.5. Pearson correlation test 
 Pearson´s ρ test was performed aiming to find significant correlations between 
methylation in gene expression patterns, within primary tumor samples. Correlations between 
gene expression and DNA methylation of the respective CpG site was tested, where correlation 
coefficient, ranges from -1 to 1. 
 This test was performed using cor.test function available in stats R package. 
 
 
3.5.6. Receiver operating characteristic (ROC curves) 
 The receiver operating characteristic (ROC) curve is a graphical representation of the 
pairs sensitivity, true positive fraction (TPR), and 1-specificity, false positive fraction (FPR). 
All cutoffs result from the coordinates that represents a compromise between sensitivity and 
specificity. This measure the quality of a diagnostic biomarker, representing the probability of 
discriminate stage I primary tumor from normal samples (Fawcett 2006; Robin et al. 2011). 
Moreover, the area under the curve (AUC) is used as an accuracy index (Fawcett 2006). 
 AUC is used as a quality measure of the curve and it is calculated through the trapezoid 
rule (Robin et al. 2011). We defined an AUC ≥ 0.8, a sensibility ≥ 0.6 and a specificity ≥  0.6 
to obtain the potential new biomarkers for further clinical applications (Greiner et al. 2000).  
ROC curves are represented in Figure 3.6A for all genes differentially expressed which presents 
CpG probes differentially methylated in lung cancer and the Figure 3.6B represents ROC 
curves considering the mentioned cutoffs criteria. 
 This analysis was performed using roc and ggroc functions available in pROC R 
package (Robin et al. 2018). 
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3.5.7. Multiple Linear Regression Model 
 Multiple linear regression (MLR) was used to analyse the relationships between a 
dependent variable (gene expression) and multiple independent variables (DNA methylation). 
The MLR was useful to verify which CpG probes are statistically significant on the variation 
of gene expression. The MLR model equation is given by, 
Figure 3.6 – ROC curve analysis of cDMGs of lung cancer. (A) All ROC curves were represented at 
various colors and (B) the selection of area under the curve (AUC) equal or greater than 0.8. Sensitivity 
represent the probability of true positives and 1-specificity represent the probability of 1-P (false 
positives), true negatives. 
A 
B 
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           eXXXXY kk   ....3322110        (1) 
where kii ,...,1,   are the weight that indicates the relative contribution for each unit measure 
of Xi in dependent variable variation. kiX i ,...,1,   are the original independent variables (Hair 
et al. 1999).  
 This analysis was performed using the lm function available in stats R package 
 
 
3.6. Cut-offs selected for DNA methylation and gene expression 
Expression databases for solid normal and stage I primary tumor samples were obtained 
through TCGAbiolinks package. Then, for each gene, the ratio between the mean of normal and 
tumor was measured and obtained foldchange value.  
Importantly, to improve the visualization of these differences, the foldchange was 
transformed by to apply the log2(Foldchange). Moreover, only genes with 
log2(Foldchange)>1.5 (up-regulated) and log2(Foldchange)<-1.5 (down-regulated) were 
considered as differentially expressed. This cut-off implies a |Foldchange|>2.82. 
 Regarding to the DNA methylation data, for each probe, the difference between the 
mean of normal and tumor beta-value (Δβ) was calculated. Here, CpG sites were considered as 
differentially methylated when Δβ>0.2 (hypermethylated) or Δβ<-0.2 (hypomethylated). 
 
 
3.7. Patterns across cancers 
  To identify common and specific, differentially expressed genes, as well as CpG sites 
differentially methylated were performed intersections across all cancer cohorts (Figure 3.7A-
B).  
 This was performed automatically through the UpSetR package in R. 
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3.8. HJ-biplot 
 HJ-Biplot (Galindo Villardón 1985) is a multivariate approach that allows to visualize 
the patient’s distribution according to the variables that more contribute to this distribution, 
considering to their norm. Since this is a data reduction technique, the patient coordinates were 
used to apply a hierarchical cluster analysis, considering the square Euclidean distance and 
using the Ward method (Hair et al. 1999). Therefore, both normal and cancer samples were 
distributed by 3 groups for all cohorts. Were strategically 3 clusters to observed possible 
undefined samples. 
 Only variables with contributions, of factor to the element, over than 0.7 were 
considered. Since this technique does not deal with missing data, these cases were replaced by 
the median value of that variable. 
 HJ-Biplot and hierarchical clusters were performed using HJ.Biplot and 
AddCluster2Biplot functions provided by the MultBiplotR R package (Vicente-villardon 2015). 
 
Figure 3.7 - Patterns across cancers analysis. (A) Gene analysis of patterns across cancers types in 
early stages. (B) CpG sites analysis of patterns across types of cancer in early stages. 
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3.9. Oncosearch algorithm 
RISmed package provides a text-mining tool that was used to query PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/) for references and selected keywords. 
Firstly, my.names function, adapted from a function provided by KEGGREST package which 
returns all designations for each gene (Figure 3.8A). Then get_refs function, created for 
searching citations in PubMed according to the association between gene to cancer, or gene to 
specific cancer, was used (Figure 3.8B). Differentially methylated genes were analyzed by sets 
and the top 10 genes were manually verified on the site. Moreover, in order to verify the veracity 
of results previously obtained a random set of genes were also manually tested. 
 
 
 
 
Figure 3.8 - Oncosearch algorithm functions. (A) my.names function is a set of instructions to provide 
all gene designations per gene, retrieves all entries from the KEGG database  (B) get_refs function 
provide a search in PubMed citations association gene to cancer or gene to specific cancer, from the 
year 1787 until 2018. 
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4 CHAPTER 4 – RESULTS 
 
 
4.1. Working pipeline 
4.1.1. Introduction 
 Creating a working algorithm that can be applied to large data cohort is a challenge. 
Considering the main goal that compares two general groups, to find significant differences in 
sets of variables, can originate potentials predictors of diagnostic and might be useful for 
disease treatment planning with faster and more reliable outputs. Here, we used DNA 
methylation and gene expression as examples of input data to validate our pipeline. 
 
4.1.2. Construction of the working pipeline 
 This working pipeline was based on statistical procedures, from data extraction to final 
outputs, with optional and complementary components (Figure 4.1). The pipeline is structured 
into 6 well defined steps:  
 
Phase 0: Optional step – Characterization of cohorts; 
Phase 1: Differential step – Identify DMG; 
Phase 2: Patterns step – Intersections across cohorts; 
Phase 3: Predictors step – Identify predictors of diagnosis; 
Phase 4: Linear models step – CpG probes with more impact in gene expression; 
Phase 5: Representation step – Multivariate approach. 
 
 The optional step (Phase 0) is based on the cohort’s characterization using clinical data 
available. Patients should be descriptively characterized with common clinical variables 
between cohorts (e.g. gender, age, histological type, therapies and classification scales) or other 
important variables for a specific cohort (e.g. estrogen receptor status, progesterone receptors 
status and HER2 receptor status specific for breast cancer).  
 Differential step (Phase 1) pretends to identify differentially methylated genes that 
resulted from significant differences between groups. For each cohort (i) were exported from 
repository two databases, DNA methylation and gene expression, with a dichotomy variable 
that defined groups (Input C). Just patients with both data were included.  
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 In the gene expression database, all samples were considered and genes without 
designation were excluded since they were not relevant in this study. In DNA methylation 
database all samples were considered with respective CpG sites and corresponded gene. Only 
CpG sites with designation and corresponding gene were established for differential analysis. 
Additionally, all outliers were removed according boxplot method. The overall result of is the 
Output 1.  
 Cohort dimension were a control criterion for decide if the algorithm proceeded 
(minimum of 20 samples per group) meaning the cohort were included or excluded and 
followed by other.  
 After the initial data pre-processing, the inferential tests were split according to the 
conclusions of each level of decisions tests. Shapiro-Wilk test is the first decision level to verify 
the normality distribution of genes or CpG probes and in case of null hypothesis rejection, p-
value<0.05, we followed a parametric approach in next level. In this case, was performed the 
t-tests according the assumptions of similar variances given (Students t-test) or unequal 
variances (Welch test). In particular, Levene test, were the equal population variances are 
tested, was the intermediate procedure before performing the t-test. Thus, the p-value results of 
t-tests decides if the two selected groups were substantially different, meaning there were 
statistically significant in differences of means between groups. The general layout of this 
sequence of tests provided us the genes differentially expressed and CpG probes differentially 
methylated. Also, an important control of p-values was, in each test, performed through a 
multiple comparison procedure (FDR<0.05) aimed to control the probability of committing any 
type I error in families of comparisons under simultaneous consideration. This short sequence 
of tests represented the core of the working pipeline. 
 Based on the previous runs tests we were able to establish the magnitude of the 
differentially expressed genes and differentially methylated CpG probes through two cut-offs,  
|log2(foldchange)| >1.5 for genes and |Δβ| > 0.2 for CpG probes (Output 2). 
 This step was concluded with correlation analysis (Pearson correlation test) between 
gene expression and DNA methylation considered only for tumor samples. Statistical 
significant correlations were saved when p-value<0.05. This final procedure completes Phase 
1 where were saved all considered differentially methylated genes (Output 3). Phase 1 
algorithm has as many iterations as the initial n of cohorts, meaning the number of outputs is 
the same of the number of cohorts.  
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 Patterns step (Phase 2) was based at intersections across cohorts that pretended find 
common genetic/epigenetic patterns with other cohorts or specifics per cohort. This step was 
only performed in the presence of more than one cohort. For Output 3 were performed an 
intersection between genes or CpG probes, and we obtained in Output 4. Then, the patterns 
across cohorts were analyzed and selected those with interest in the study context.  
 Predictors step (Phase 3) pretended identify epigenetic diagnostic biomarkers through 
the Output 3. For each cohort, was performed a ROC curve analysis to identify genes and CpG 
probes with the power to predict diagnosis. For this, were establish three cut-offs: AUC > 0.8, 
sensibility>0.6 and specificity>0.6. Those potential Genes and CpG probes revealed good 
influence discrimination between groups (Output 5). This output may play an important clinical 
role.  
 Linear models step (Phase 4) for identify CpG probes with more impact in gene 
expression, that is, CpG probes which are the best linear predictors in gene expression. For each 
cohort, were performed an MLR model analysis using Output 3, considering gene expression 
as the dependent variable and respective CpG probes as independent variables. CpG probes 
with p-value<0.05 were considerate statistically significant, and genes without significant CpG 
probes were excluded (Output 6). This step was important to check the which CpG probes are 
really important in gene expression variation.  
 Representation step (Phase 5) based on the multivariate technique, the HJ-Biplot. For 
each cohort, using Output 3. Gene expression or DNA methylation coordinates from HJ-Biplot 
were plotted in a principal plane (more accumulative variance, plan 1-2). Since the distribution 
of patients is influenced by gene expression or DNA methylation, the HJ-Biplot representation 
allowed better understanding of the impact of these variables in clustering behavior of samples.  
Additionally, to remove noise and select better explicability from genes and DNA methylation, 
were considered variables with contributions≥0.7. Hierarchical clustering of samples was 
performed based on HJ-Biplot coordinates, considering the ward method and the Euclidean 
distance. Results were presented in HJ-Biplot representation (Output 7). 
 Once the work pipeline was structured, we test the cohorts in The Cancer Genome Atlas 
(TCGA) database. 33 TCGA cohorts were available online and submitted to Phase 0 and Phase 
1. Only 8 cohorts with solid tissue normal and primary tumor stage I samples (see in methods) 
results from previous phases, and there were: 
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Cohort 1 – Breast Invasive Carcinoma (TCGA-BRCA); 
Cohort 2 – Colorectal Adenocarcinoma (TCGA-COADREAD); 
Cohort 3 – Head and Neck Squamous Cell Carcinoma (TCGA-HNSC); 
Cohort 4 – Kidney Renal Clear Cell Carcinoma (TCGA-KIRC); 
Cohort 5 – Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP); 
Cohort 6 – Liver Hepatocellular Carcinoma (TCGA-LIHC); 
Cohort 7 – Lung Adenocarcinoma (TCGA-LUAD); 
Cohort 8 – Thyroid Carcinoma (TCGA-THCA) 
  
 This working pipeline section answers the first objective of this study and supports the 
others. The Phase 1 answers the second aim: “Identify cancer differentially methylated genes 
(cDMGs) in early stages”, Phase 2 answers the third aim: “Identify patterns across cancers” 
and Phase 3 answers the fourth and last aim: “Identify epigenetic biomarkers that predict 
diagnosis”. Any other Phases were additional or complementary analysis that might be of 
interest to the researchers. 
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4.1.3. Working pipeline 
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Figure 4.1 - Working pipeline. In Principal component, exists four Phases: 0. optional step, 1. 
differential step, 2. patterns step and 3. predictors step. Optional step (Phase 0) is based on the cohort’s 
characterization using clinical data available. Differential step (Phase 1) pretends identify differentially 
methylated genes that presents significant differences between groups using gene expression and DNA 
methylation databases. After data preprocess, the normality distribution of genes and CpG probes were 
verified to be chosen in parametric or nonparametric way by Shapiro-Wilk test decision. Nonparametric 
way uses Mann-Whitney U test to check differences between group distributions. Before parametric 
way, similar variances were checked trough Levene test, and t-test were performed for equal or unequal 
variances (Welch test). These two ways were complemented with false positives correction procedure 
were FDR < 0.05. Then, were established two cut-offs, |log2(Foldchange)|>1.5 and |Δβ|>0.2. Pearson 
coefficient was used to verify correlations between genes and CpG probes in tumor group and select 
differentially methylated genes. This Phase 1 iterates per cohort and save the respective outputs. Two 
steps followed, using the Output 3, were designated patterns-step (Phase 2) and predictors-step (Phase 
3). Phase 2 is based on intersection of genes or CpG across cohorts resulting in common patterns or 
specifics in each one. Predictors-Phase identify genes and CpG probes as good predictors of diagnosis 
based in ROC curve analysis, considering AUC > 0.8, sensibility >0.6 and specificity >0.6. In 
Complementary component, exist two Phases: 4. Linear models step and 5. Representation step. 
Linear models step (Phase 4) pretend to obtain CpG probes that has good predictors of gene expression 
trough MLR (p-value < 0.05). Representation step (Phase 5) is based on HJ-Biplot representation of 
gene expression or DNA methylation were samples are distributed in a maximum retain variance 
scenario (plan). Samples were grouped trough hierarchical clustering, using Ward method and Euclidian 
distance.   
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4.2. Identification of cancer differentially methylated genes (cDMGs) – Phase I 
4.2.1. Introduction 
 Initially, we performed Phase 1 of the WP to identify cancer differentially methylated 
genes. Early stages analysis presupposes the existence of stage I primary tumor and solid tissue 
normal samples. All Genes and CpG sites probes for whole-genome were considered. A 
selecting procedure were computed for each type of cancer, and saved genes differentially 
expressed associated with differentially methylated CpG probes were saved. 
 
4.2.2. Identification of cDMGs per cohort 
 We extracted expression for 20531 genes and methylation of 485577 CpG probes 
through pre-processing, the initial procedure of Phase 1. Missing gene expression values and 
nonidentity gene were excluded (Figure 4.2A). 20502 genes and 364643 CpG probes became 
available for analysis (Figure 4.2B). All 8 cohorts were submitted into Phase I to evaluate the 
differences between normal and tumor groups. Results reveals gene sets and respective CpG 
probes across for each type of cancer (Figure 4.2C, Appendix 1). Colorectal cancer has 307 
cDMGs associated with 924 CpG probes, breast cancer has 117 with 368, head and neck cancer 
have 99 with 292, kidneyR cancer has 156 with 299, kidneyP has 106 with 224, liver cancer has 
349 with 1453, lung cancer has 180 with 601 and thyroid cancer 25 with 40, respectively. 
Colorectal and Liver cancers were the cancers with more genes and CpG probes and thyroid 
cancer with fewer alterations.  
 We checked how many CpG probes regulated negatively and positively the up-regulated 
and down-regulated genes (Figure 4.2D). As a result, down-regulated genes were associated 
with hypermethylated and hypomethylated CpG probes for all cancers: head and neck cancer 
present 148 and 70, lung cancer present 74 and 61, liver cancer present 31 and 691, colorectal 
present 451 and 245, thyroid cancer present 2 and 3, breast cancer present 74 and 107, kidneyR 
present 157 and 69 and kidneyP present 112 and 39, respectively. Also, up-regulated genes were 
associated with hypermethylated and hypomethylated CpG probes: head and neck cancer 
present 65 and 9, lung cancer present 429 and 37, liver cancer present 113 and 618, colorectal 
present 146 and 82, thyroid cancer present 1 and 34, breast cancer present 123 and 64, kidneyR 
present 15 and 58 and kidneyP present 50 and 23, respectively.   
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 This Phase allowed ranked, trough up-regulated and down-regulated classification, a top 
five list of genes for each cancer cohort (Table 4.1). Starting with cancers that have more up-
regulated genes which are: breast, liver, lung and thyroid, and those that had more down-
regulated genes: colorectal, head and neck, kidneyR and kidneyP cancers. CpG probes were 
divided by the up or down regulated gene and classified in hyper- methylated and hypo- 
methylated (Figure 4.2D). Despite thyroid cancer in spite of presents few alterations, the 
majority of upregulated genes are associated to hypomethylated probes. Most cancers present 
more CpG probes hypermethylated in early stages, except for lung and thyroid cancers. 
 
Figure 4.2 – Cancer differentially methylated genes (cDMGs). (A) Number of genes and CpG probes 
exported from The Cancer Genome Atlas (TCGA) database. Gene expression was measured using 
Illumina Hiseq platform and DNA methylation by Illumina HumanMethylation 450. (B) Number of 
genes and CpG probes resulting from pre-processing of data. Missing values, non-identified genes and 
CpG probes, and CpG probes without matching gene was excluded. (C) Inferential statistical analysis 
applied for all cohorts with FDR < 0.05. (D) Pattern of upregulated and downregulated genes for all 
cohorts, and frequencies of hypermethylated and hypomethylated considering gene pattern type. 
53 
 
Table  4.1 – Top five genes for mostly up-regulated or down-regulated cohorts. 
 
 
 
4.2.3. CpG probes localization 
 Modified CpG probes for each cohort were distributed considering their location in 5 
different sites: 5'UTR, TSS1500, TSS200, 1st Exon, Body and 3'UTR. In Figure 4.3 are 
represented frequency and proportion of CpG probes per site, considering only CpG probes 
with a single localization (Appendix 3). Mostly CpG probes are located in gene body, except 
in thyroid cancer, that there was a large proportion of CpG sites located on transcription start 
sites. 
Cohort 
Up-regulated 
genes 
Log2(foldchange) Cohort 
Down-
regulated 
genes 
Log2(foldchange) 
Breast cancer 
TLX1NB 5.246988909 
Colorectal 
cancer 
CACNG5 -5.052460275 
METTL11B 4.624172361 GABRG1 -4.677518094 
APOBEC1 3.713445213 HTR3B -4.59866826 
EFNA2 3.68424939 CLVS2 -4.216960803 
SP8 3.609379941 MCHR2 -4.005016352 
Liver cancer 
CTAG2 5.999762549 
Head and 
neck 
cancer 
NKAIN3 -5.189842923 
NAA11 5.824472442 PRAMEF12 -4.87102028 
REG1B 5.720864063 ACCSL -4.465862478 
COX7B2 5.533620437 PROKR2 -3.999350407 
CDH9 5.501310695 CSN2 -3.872931671 
Lung cancer 
TFAP2D 6.177427934 
KidneyR 
cancer 
DEFB132 -4.666355345 
PITX2 5.551557746 ROS1 -3.616624535 
SP8 5.35736266 VGLL1 -3.550205623 
HOTAIR 5.346610236 OLFM3 -3.429478559 
FOXI3 5.256633941 FXYD4 -3.323236545 
Thyroid 
cancer 
PLA2G2E 7.060822742 
KidneyP 
cancer 
CGA -5.499764391 
MS4A15 4.458326797 CPNE6 -4.838612363 
CSF2 3.55921961 C16orf11 -4.007789014 
AWAT2 3.513327584 AMELY -3.976773857 
RNASE11 3.444127322 BSND -3.896258476 
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4.2.4. Gene-annotation enrichment analysis 
 To evaluate the Gene Ontology (GO) of cDMGs by each type of cancer an enrichment 
analysis was performed using DAVID (https://david.ncifcrf.gov/ ), version 6.8, available 
online. Use default fields except that we defined as p-value<0.05. Rich-factor is the ratio of the 
number of cDMGs mapped to this GO term with total annotated in this term (Wang et al. 2016).  
 Results reveals the existence of some very significant gene terms in development, 
synaptic transmission, signaling and transport (Figure 4.4, Appendix 4). Breast cancer reveals 
very enrichment genes in the dorsal/ventral formation pattern (p-value=0.0005 and rich-
factor=0.125). Colorectal cancer reveals very enrichment genes in the chemical synaptic 
transmission (p-value=1.309E-10). Head and neck cancer is highly enriched in ionotropic 
glutamate receptor signaling (p-value=0.0002 and rich-factor=0.167). KidneyR cancer is highly 
enriched in genes associated with excretion (p-value = 0.002 and rich-factor=0.108). KidneyP 
cancer is more enriched in genes associated with kidney development (p-value=0.009 and rich-
factor=0.047). Liver cancer is enriched in visual perception (p-value=0.0001 and rich-
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Figure 4.3 – CpG sites localization for each type of cancer. CpG probes can be in 5 main sites: 
TSS1500, TSS200, 5'UTR, 1stExon, Body, 3'UTR. TSS1500 - 1500bp upstream to Transcription Start 
Site (grey); TSS200 – 200bp upstream to Transcription Start Site (green); 5'UTR - Five prime 
untranslated region (blue); 1stExon – First exon of gene (orange); Body – Gene body (yellow); 3'UTR 
- Three prime untranslated region (pink). Only probes with single localization were represented. 
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factor=0.137) and neurotransmitter secretion (p-value=0.0002 and rich-factor=0.137). Insight, 
that thyroid cancer due to its number of genes did not present results. 
 
 
Figure 4.4 – Cancer-associated differentially methylated genes (cDMGs) identified in 7 cohorts. 
Scatterplot for statistics of biological enrichment. For all gene lists, we listed the top five enriched 
biological processes. Rich-factor is the ratio of the number of cDMGs mapped to this GO term with total 
annotated in this term, From: Wang et al. 2016. The higher rich factor means is the more significant 
enrichment. The higher -log10(p) also means the more significant enrichment, where p is the p-value 
for GO term. TCGA-BRCA – Breast Invasive Carcinoma; TCGA-COADREAD – Colorectal 
Adenocarcinoma; TCGA-HNSC – Head and Neck Squamous Cell Carcinoma; TCGA-KIRC – Kidney 
Renal Clear Cell Carcinoma; TCGA-KIRP – Kidney Renal Papillary Cell Carcinoma; TCGA-LIHC – 
Liver Hepatocellular Carcinoma. TCGA-THCA – Thyroid Carcinoma due to its reduced number of 
genes does not present results. 
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4.2.5. Analysis of annotation in the literature 
 Differential methylated genes in early stages were evaluated for their annotation in the 
literature with the algorithm called "Oncosearch" (see in the methods). The presence of cDMGs 
associated with the respective cancers gives consistency to the analysis and, however, not 
reported annotation genes might suggest clinical potential in diagnosis.  
 Associations between genes with cancer for each cohort gave us genes that are mostly 
reported in cancer type (Appendix 5). We verified that only a small set gene of was linked in 
cancer. Similar proportions in Figure 4.5, tells us that approximately 13% weren´t reported in 
cancer. We also can see some reported genes in cancer in general: COL9A1, CD5L, SLC4A1, 
CALCA, PROC, TNFSF14, SLC6A2, TMEFF2, CSF2 and SPINK5, related to body metabolism 
and homeostasis. Within genes never mentioned in cancer some of them are the following: 
KCNJ9, GLB1L3, SLC27A6, SLC38A8, FLJ12825, HIST1H4E, FRMPD4, DCDC2B, 
DMRTA2, NXF5, associated with distinct function in human body.  
 In cancer reported genes, approximately 87%, we had two scenarios (Figure 4.5): 
firstly, the cancers like thyroid, liver, kidney, and head and neck that had more genes not 
referenced in specific cancers, and, secondly, the cancers like: lung, breast and colorectal that 
had more referenced genes in specific cancers. 
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4.3. Specific methylation patterns across different cancers – Phase 2 
4.3.1. Introduction 
 Genetic and epigenetic patterns were used to explore behavior among different types of 
cancer, aimed to find common or unique patterns according to the Phase 2 of the WP. 
Completed this analysis, we focused on common biological patterns that allowed us to 
characterize basic tumorigenesis, or specific pattern to create an interest pattern suported on 
new potential diagnosis biomarker. 
 
4.3.2. Crossing different cancers 
 Identification of genetic and epigenetic patterns occurred by crossing the sets of genes 
and CpG probes of each type of cancer. The intersections trough all cohorts results in 
combinations of common or unique patterns that might characterize the tumor development. 
The results reveal the existence of a set of common genes and several specific genes for each 
type of cancer (Figure 4.6A). Those specific genes were distributed by cohort: 18 in thyroid 
cancer, 49 in head and neck, 70 in kidneyP, 55 in breast cancer, 100 in kidneyR, 97 in lung 
cancer, 202 in colorectal and 240 in liver cancer (Appendix 2). Despite the high complexity of 
patterns, we saw that most behavior is characterized by particular genes. However, in 
adenocarcinomas, colorectal and lung cancers, presented 21 common genes. KidneyR and 
KidneyP cancers presented 13 common genes.  
 CpG probes have the same pattern results as the genes (Figure 4.6B). Those specific 
CpG probes were distributed by cohort: thyroid cancer with 35, head and neck cancer with 223, 
kidneyP cancer with 189, breast cancer with 261, kidneyR cancer with 244, lung cancer with 
449, colorectal cancer with 782 and liver cancer with 1339.  
 In summary, the results reveal a specific pattern of cDMGs for each early stage cancer 
that showed to be unique in cancer development. 
 
Figure 4.5 – Annotation analysis for cDMGs in literature using Oncosearch Algorithm. Association 
between cDMGs and cancer or specific cancer were performed by Oncosearch algorithm. Oncosearch 
algorithm use PubMed repository to search query citations. Grey represents genes without cancer 
references and green with references in cancer. Genes associated with cancer but not reported in specific 
cohorts were represented in blue. In yellow were genes that associated with specific cohort. 
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Figure 4.6 – Crossing different cancers. (A) represent the cDMGs patterns across cancers. (B) 
represented the CpG probes patterns across cancers. Blue represents the size cohort. The intersection of 
cDMGs is represented in graph. The single points represented the genes or CpG probes that are unique 
in each cancer. TCGA-BRCA – Breast Invasive Carcinoma; TCGA-COAD/READ – Colorectal 
Adenocarcinoma; TCGA-HNSC – Head and Neck Squamous Cell Carcinoma; TCGA-THCA – Thyroid 
Carcinoma; TCGA-KIRC – Kidney Renal Clear Cell Carcinoma; TCGA-KIRP – Kidney Renal 
Papillary Cell Carcinoma; TCGA-LIHC – Liver Hepatocellular Carcinoma. 
A 
B 
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4.3.3. Pathways characterization of the specific cDMGs  
 After identifying specific gene patterns for each type of cancer, we performed an 
enrichment analysis of pathways using the Reactome Pathways Database, helped with DAVID 
tool previously used. The default criteria were used and p-value<0.05. 
 Pathways results analysis reveal some enrichment pathways, the most significant being 
represented in Table 4.2. It was important described which cancers presented significant 
enrichment pathways (Appendix 6).  
 For early stages, specific changes in colorectal cancer were strongly associated with 
RAF/MAP kinase cascade (p-value = 8.01E-05) through the genes: FGF19, FGF8, GRIN2A, 
IL5RA, FGF20, NEFL, FGF3 and GFRA3; PI3K Cascade (p-value = 0.004096) through the 
genes: FGF19, FGF8, FGF20 and FGF3; and L1CAM interactions (p-value = 0.004208) 
through the genes: CNTN2, CNTN1 and NCAN.  
 Head and neck cancer is associated with GABA A receptor activation (p-value = 
0.026896) and Neurotransmitter receptors and postsynaptic signal transmission (p-value = 
0.028936) through the genes: GABRG3 and GABRB1; Negative regulation of TCF-dependent 
signaling by WNT ligand antagonists (p-value = 0.030972) through the genes: SOST and WIF1; 
and G alpha (q) signaling events (p-value = 0.045894) through the genes: NPFFR2, PROKR2 
and TRH.  
 Lung cancer, the most significant pathways were Peptide ligand-binding receptors (p-
value = 0.006942) through the genes: SSTR4, EDN3, NPBWR1 and OPRD1; and RNA 
Polymerase I Promoter Opening (p-value = 0.023072), DNA methylation (p-value = 
0.024459), Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes 
KLK2 and KLK3 (p-value = 0.025879) all through the genes: HIST1H2BI, HIST1H3B and 
HIST1H4E.  
 KidneyP cancer is associated with Ion homeostasis (p-value = 0.015509) through the 
genes: FXYD3, CAMK2A and CASQ2.  
 Liver cancer is associated with: Collagen biosynthesis and modifying enzymes (p-value 
= 0.031157) through the genes: COL6A6, COL25A1, COL2A1 and COL24A1; Glucagon-type 
ligand receptors (p-value = 0.037531) through the genes: GLP2R, GLP1R and GHRHR; 
Adheres junctions interactions (p-value = 0.042236) through the genes: CDH8, CDH9 and 
CDH10; and Signaling by PDGF (p-value = 0.042236) through the genes: COL6A6, COL2A1 
and THBS4. Importantly, breast, kidneyR and thyroid cancers had no significant results. 
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Table  4.2 – Pathways enrichment analysis for specific genes for each type of cancer. 
 
Cohort Term Count p-value Genes 
Colorectal 
cancer 
R-HSA-5673001: RAF/MAP kinase cascade 8 8.01E-05 
FGF19, FGF8, GRIN2A, IL5RA, 
FGF20, NEFL, FGF3, GFRA3 
R-HSA-109704: PI3K Cascade 4 0.004096 FGF19, FGF8, FGF20, FGF3 
R-HSA-373760: L1CAM interactions 3 0.004208 CNTN2, CNTN1, NCAN 
Head and 
Neck cancer 
R-HSA-977441: GABA A receptor activation 2 0.026896 GABRG3, GABRB1 
R-HSA-112314: Neurotransmitter receptors and 
postsynaptic signal transmission 
2 0.028936 GABRG3, GABRB1 
R-HSA-3772470: Negative regulation of TCF-dependent 
signaling by WNT ligand antagonists 
2 0.030972 SOST, WIF1 
R-HSA-416476: G alpha (q) signalling events 3 0.045894 NPFFR2, PROKR2, TRH 
Lung 
cancer 
R-HSA-375276: Peptide ligand-binding receptors 4 0.006942 SSTR4, EDN3, NPBWR1, OPRD1 
R-HSA-73728: RNA Polymerase I Promoter Opening 3 0.023072 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-5334118: DNA methylation 3 0.024459 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-5625886: Activated PKN1 stimulates 
transcription of AR (androgen receptor) regulated genes 
KLK2 and KLK3 
3 0.025879 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-427359: SIRT1 negatively regulates rRNA 
expression 
3 0.026601 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-212300: PRC2 methylates histones and DNA 3 0.030335 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-2299718: Condensation of Prophase 
Chromosomes 
3 0.031105 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-912446: Meiotic recombination 3 0.041806 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-201722: Formation of the beta-catenin:TCF 
transactivating complex 
3 0.042679 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-73777: RNA Polymerase I Chain Elongation 3 0.044447 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-5250924: B-WICH complex positively regulates 
rRNA expression 
3 0.045341 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
R-HSA-3214815: HDACs deacetylate histones 3 0.048063 
HIST1H2BI, HIST1H3B, 
HIST1H4E 
KidneyP 
cancer 
R-HSA-5578775: Ion homeostasis 3 0.015509 FXYD3, CAMK2A, CASQ2 
Liver 
cancer 
R-HSA-1650814: Collagen biosynthesis and modifying 
enzymes 
4 0.031157 
COL6A6, COL25A1, COL2A1, 
COL24A1 
R-HSA-420092:  Glucagon-type ligand receptors 3 0.037531 GLP2R, GLP1R, GHRHR 
R-HSA-418990: Adherens junctions interactions 3 0.042236 CDH8, CDH9, CDH10 
R-HSA-186797: Signaling by PDGF 3 0.042236 COL6A6, COL2A1, THBS4 
61 
 
4.4. Identification of biomarkers with clinical application – Phase 3 
4.4.1. Introduction 
 Diagnostic biomarkers are essential for identify early stages in cancer. Find new 
biomarkers that can discriminate cancer outcome with high levels of sensitivity and specificity, 
become a truly powerful tool for clinicians in order to predict or adjust better diagnosis. Phase 
3 of the working pipeline is to performer those analyses. 
 
4.4.2. cDMGs predict diagnostic of patients with cancer in early stages 
 ROC curve is the most common analysis for study evaluation in order to identify 
cDMGs as good predictors of cancer diagnostic. We intend to identify biomarkers that have the 
capacity to discriminate normal from tumor tissue for each type of cancer, and eventually 
distinguish cancers (Appendix 7).  
 Breast cancer has 45 genes and 340 CpG probes as good diagnosis predictors, but only 
165 CpG probes were corresponded with the 45 genes. However, looking at the specific 
patterns, just 19 genes with 44 CpG sites revealed as potential diagnostic predictors for breast 
cancer.  
 Colorectal cancer has 238 genes and 835 CpG probes as good diagnosis predictors, but 
only 673 CpG probes corresponded with the 238 genes. However, looking at the specific 
patterns, just 153 genes with 461 CpG sites revealed as potential diagnostic predictors for 
colorectal cancer. 
 Head and neck cancer has 57 genes and 286 CpG probes as good diagnosis predictors, 
but only 156 CpG probes corresponded with the 57 genes. However, looking at the specific 
patterns, just 27 genes with 68 CpG sites revealed as potential diagnostic predictors for head 
and neck cancer. 
 KidneyR cancer has 142 genes and 299 CpG probes as good diagnosis predictors, but 
only 271 CpG probes corresponded with the 142 genes. However, looking at the specific 
patterns, just 93 genes with 173 CpG sites revealed as potential diagnostic predictors for 
kidneyR cancer. 
 KidneyP cancer has 88 genes and 200 CpG probes as good diagnosis predictors, but only 
181 CpG probes corresponded with the 88 genes. However, looking at the specific patterns, just 
53 genes with 111 CpG sites revealed as potential diagnostic predictors for kidneyP cancer. 
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 Liver cancer has 126 genes and 1129 CpG probes as good diagnosis predictors, but only 
619 CpG probes corresponded with the 126 genes. However, looking at the specific patterns, 
just 72 genes with 261 CpG sites revealed as potential diagnostic predictors for liver cancer. 
 Lung cancer has 88 genes and 595 CpG probes as good diagnosis predictors, but only 
280 CpG probes corresponded with the 88 genes. However, looking at the specific patterns, just 
38 genes with 128 CpG sites were revealed as potential diagnostic predictors for lung cancer. 
 Thyroid cancer has 18 genes and 38 CpG probes as good diagnosis predictors, but only 
29 CpG probes corresponded with the 18 genes. However, looking at the specific patterns, just 
14 genes with 24 CpG sites revealed as potential diagnostic predictors for thyroid cancer. 
 In summary, our results revealed that not all genes and CpG probes are good predictors 
of diagnostic, but a Specific pattern analysis revealed some sets of predictors in diagnostic for 
specific tumor types.  
 
 
4.5. Complementary component 
4.5.1. Introduction 
 A complementary component of WP intended to analyze the relations between genes 
and CpG probes wondering which methylation of CpG probes is effectively important in gene 
expression, using multiple linear regression analysis (Phase 4). Also, a multivariate approach, 
HJ-Biplot, where samples and genes (or CpG probes) are simultaneously presented in graphic 
layout, were useful for identifying cluster behaviors considering the most important genes or 
CpG probes in samples distribution (Phase 5). 
 
4.5.2. CpG sites with more importance per gene – Phase 4 
 The followed analysis aimed to identify, which CpG probes were statically significant 
in gene variations that might be in origin of normal-tumor transition.  
 Results showed that, within cDMGs with more than one differentially methylated CpG 
probe, there existed methylation positions which play a more significant role in order to explain 
gene expression (Appendix 8). Assuming more demanding criteria related to p-values we 
considered, in this context, p-values<0.0005, which resulted in 71 CpG probes (57%). 
 Breast cancer has 125 significant CpG probes that are distributed throughout gene 
considering only the probes with a single localization as followed: 27% TSS1500, 17% 
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TSS200, 8% 5UTR, 2% 1st exon, 39% body and 4% 3'UTR. Assuming more demanding 
criteria related to the p-values we considered, in this context, p-values<0.0005, which resulted 
in 71 CpG probes (57%). It should be noted that the majority of methylation of CpG probes 
were within an accurate range showing a strong relationship with the respective gene 
expression. The selected the 71 CpG probes corresponds to 63 genes that: 28 has CpG sites 
with single localization belong to the specific pattern for breast cancer. The top 20 most 
significant CpG probes are represented in Table 4.3. 
 
Table  4.3 – Top 20 of most significant CpG probes selected for breast cancer based on the MLR 
analysis.  
cg Gene Localization Delta-beta p-value 
cg01747222 CMTM5 TSS200 0.262727 1.28E-33 
cg15615793 CRHR2 TSS1500 0.24681 1.40E-15 
cg05426601 CPA1 TSS1500 0.200353 2.86E-15 
cg13696490 LOC201651 TSS1500 0.261073 3.65E-14 
cg00635343 LOC642597 Body -0.2126 3.97E-13 
cg07504127 CLDN25 TSS1500 -0.23736 6.51E-12 
cg10316270 RBM46 TSS200 -0.21748 1.17E-11 
cg03543319 PROKR1 Body -0.23093 1.70E-11 
cg16310003 HPD TSS1500 0.249793 8.51E-11 
cg20742415 METTL11B TSS1500 -0.26241 1.99E-10 
cg17085688 GNGT1 Body 0.208609 2.47E-10 
cg26925231 SGCZ Body 0.273407 4.65E-10 
cg01479664 TEPP Body -0.23518 5.58E-10 
cg11473616 CYP1A2 TSS200 -0.22304 1.80E-09 
cg01454519 CST5 1stExon -0.21741 3.32E-09 
cg01595325 HS3ST4 Body -0.22664 8.13E-09 
cg04561937 GAB4 3'UTR -0.20994 8.34E-08 
cg21977377 NKX2-2 Body 0.26497 1.10E-07 
cg10322419 LOC284661 TSS1500 -0.26566 1.26E-07 
cg07197831 DNAJC5G 3'UTR -0.24136 2.90E-07 
 
 
 Colorectal cancer has 302 significant CpG probes that are distributed throughout gene 
considering only the probes with a single localization as followed: 27% TSS1500, 17% 
TSS200, 8% 5UTR, 2% 1st exon, 39% body and 4% 3'UTR. Assuming more demanding 
criteria related to p-values we considered, in this context, p-values<0.0005, which resulted in 
144 CpG probes (48%). It should be noted that the majority of methylation of CpG probes were 
within an accurate range showing a strong relationship with the respective gene expression. The 
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selected the 144 CpG probes corresponds to 121 genes that: 80 has CpG sites with single 
localization belong to the specific pattern for colorectal cancer. The top 20 most significant 
CpG probes are represented in Table 4.4. 
 
Table  4.4 – Top 20 of most significant CpG probes selected for colorectal cancer based on the 
MLR analysis. 
cg Gene Localization Delta-beta p-value 
cg14075424 NANOS3 1stExon -0.20987 3.13E-24 
cg01618102 BAI3 Body -0.49695 4.79E-23 
cg20950932 GRIA3 TSS1500 0.315462 1.18E-16 
cg03609960 ANKS1B Body 0.387767 2.10E-16 
cg00618450 SEZ6L Body 0.391342 5.22E-16 
cg16415058 SORCS1 1stExon 0.278692 1.04E-15 
cg10735632 C2orf40 TSS1500 0.284777 1.44E-15 
cg26165108 ENPP6 Body -0.36758 3.13E-15 
cg04306063 CRHBP Body 0.258118 1.32E-14 
cg20752831 RIMS4 3'UTR -0.20803 1.50E-14 
cg12232463 LONRF2 Body -0.39412 3.65E-14 
cg08104310 ASTN1 3'UTR -0.31812 1.17E-13 
cg01162507 GP2 3'UTR -0.27092 2.64E-13 
cg16080876 NEFL 1stExon 0.30605 3.03E-13 
cg13206017 SST TSS200 0.330157 9.84E-13 
cg04678336 SGCG Body -0.25889 1.76E-12 
cg01201932 CMA1 TSS1500 -0.35601 9.19E-12 
cg02739437 SPOCK3 TSS1500 -0.28411 1.79E-11 
cg20944283 CADM3 3'UTR -0.32134 2.61E-11 
cg09442828 ADRB3 1stExon 0.24909 3.29E-11 
 
 
 
 Head and neck cancer has 71 significant CpG probes that are distributed throughout 
gene considering only the probes with a single localization as followed: 27% TSS1500, 17% 
TSS200, 8% 5UTR, 2% 1st exon, 39% body and 4% 3'UTR. Assuming more demanding 
criteria related to p-values we considered, in this context, p-values<0.0005, which resulted in 
32 CpG probes (45%). It should be noted that the majority of methylation of CpG probes were 
within an accurate range showing a strong relationship with the respective gene expression. The 
selected the 32 CpG probes corresponds to 31 genes that: 15 has CpG sites with single 
localization belong to the specific pattern for head and neck cancer. The 15 most significant 
CpG probes are represented in Table 4.5. 
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Table  4.5 – Top 15 of most significant CpG probes selected for head and neck cancer based on 
the MLR analysis. 
cg Gene Localization Delta-beta p-value 
cg16001323 ADH1B 3'UTR -0.22058 2.85E-10 
cg03222834 SHISA9 Body -0.22171 3.95E-10 
cg16638385 SOST Body 0.364031 3.87E-08 
cg02598319 C6 Body -0.274 1.51E-07 
cg11027140 GPR144 TSS1500 0.229374 1.52E-07 
cg21171320 TRPM3 Body -0.32901 2.66E-07 
cg13672800 C20orf141 TSS1500 -0.25299 1.20E-06 
cg18950108 DPCR1 Body -0.24163 1.83E-06 
cg06418867 C10orf90 Body -0.2098 6.77E-06 
cg24566400 RBP4 TSS1500 0.223605 1.41E-05 
cg19112977 MGC16121 Body 0.317332 2.21E-05 
cg20646280 KCTD8 1stExon 0.2793 2.31E-05 
cg11213520 LHX5 Body 0.354345 5.92E-05 
cg02227188 HOXC9 Body 0.366655 0.000153 
cg24157814 DCT Body -0.20058 0.000312 
 
 
 
 
 
 
 KidneyR cancer has 202 significant CpG probes that are distributed throughout gene 
considering only the probes with a single localization as followed: 27% TSS1500, 17% 
TSS200, 8% 5UTR, 2% 1st exon, 39% body and 4% 3'UTR. Assuming more demanding 
criteria related to p-values we considered, in this context, p-values<0.0005, which resulted in 
146 CpG probes (72%). It should be noted that the majority of methylation of CpG probes were 
within an accurate range showing a strong relationship with the respective gene expression. The 
selected the 146 CpG probes corresponds to 119 genes that: 87 has CpG sites with single 
localization belong to the specific pattern for kidneyR cancer. The top 20 most significant CpG 
probes are represented in Table 4.6. 
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Table  4.6 – Top 20 of most significant CpG probes selected for KidneyR cancer based on the MLR 
analysis. 
cg Gene Localization Delta-beta p-value 
cg20610181 CA9 1stExon -0.3922 4.58E-59 
cg04511534 GGT6 Body 0.39297 4.89E-52 
cg18390495 DEFB132 Body -0.26447 3.76E-44 
cg03762549 TMEM61 Body 0.239261 2.73E-42 
cg13540480 C14orf50 TSS1500 0.283084 7.32E-41 
cg07795964 NAT8L 3'UTR 0.253435 3.73E-35 
cg08842032 EPN3 5'UTR 0.355429 4.41E-31 
cg14895298 BIRC7 TSS200 -0.24693 8.66E-31 
cg00373436 TAGLN3 Body -0.3479 2.32E-29 
cg21504505 C4orf6 3'UTR -0.24695 5.47E-28 
cg14021961 CLCNKA 5'UTR 0.223245 1.37E-24 
cg10958362 C5orf38 Body -0.21964 9.74E-23 
cg13929970 FGFBP1 5'UTR 0.236362 7.41E-22 
cg08568550 C11orf16 TSS200 0.23572 4.98E-21 
cg10896586 GPR110 5'UTR 0.263813 5.03E-21 
cg03211864 BTBD16 Body -0.23755 7.16E-21 
cg16804165 CKMT1A Body -0.26004 1.92E-20 
cg10362335 TNFSF14 5'UTR -0.20133 5.52E-20 
cg25649889 MYO3B Body 0.31116 9.35E-20 
cg18565355 ESRP1 Body 0.280886 2.97E-19 
 
 
 
 
 KidneyP cancer has 119 significant CpG probes that are distributed throughout gene 
considering only the probes with a single localization as followed: 27% TSS1500, 17% 
TSS200, 8% 5UTR, 2% 1st exon, 39% body and 4% 3'UTR. Assuming more demanding 
criteria related to p-values we considered, in this context, p-values<0.0005, which resulted in 
91 CpG probes (76%). It should be noted that the majority of methylation of CpG probes were 
within an accurate range showing a strong relationship with the respective gene expression. The 
selected the 91 CpG probes corresponds to 76 genes that: 55 has CpG sites with single 
localization belong to the specific pattern for kidneyp cancer. The top 20 most significant are 
represented in Table 4.7. 
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Table  4.7 – Top 20 of most significant CpG probes selected for KidneyP cancer based on the MLR 
analysis. 
cg Gene Localization Delta-beta p-value 
cg04389897 TFAP2A 3'UTR -0.23457 1.22E-42 
cg10938046 C6orf223 Body 0.328454 3.56E-39 
cg00061039 F11 TSS200 0.253093 2.26E-29 
cg09075137 SCEL 3'UTR 0.289281 1.93E-28 
cg16146033 SLC22A8 Body -0.23207 2.69E-28 
cg16806210 TTC36 1stExon 0.232749 1.52E-26 
cg07493760 SLC4A9 TSS200 0.249099 1.40E-24 
cg00144673 MCCD1 Body 0.303626 9.66E-24 
cg03180302 TTR 1stExon 0.260254 5.62E-22 
cg20688289 MUC12 TSS200 0.292753 3.36E-21 
cg26433444 PI16 3'UTR 0.202948 5.93E-21 
cg00498289 GCKR 1stExon -0.28471 1.34E-19 
cg11769400 PEBP4 Body -0.30956 1.69E-18 
cg19765377 MAT1A TSS1500 0.205119 9.55E-18 
cg14635269 LMX1B Body -0.26171 5.76E-17 
cg08622198 CHRM3 5'UTR -0.39448 3.32E-16 
cg10974219 MYOCD 3'UTR -0.34818 3.25E-15 
cg16510654 C1orf64 TSS200 0.219073 8.19E-15 
cg02704949 FXYD3 5'UTR 0.28631 9.15E-15 
cg22324567 EBF2 Body -0.20462 1.37E-13 
 
 
 
 
 Liver cancer has 425 significant CpG probes that are distributed throughout gene 
considering only the probes with a single localization as followed: 27% TSS1500, 17% 
TSS200, 8% 5UTR, 2% 1st exon, 39% body and 4% 3'UTR. Assuming more demanding 
criteria related to p-values we considered, in this context, p-values<0.0005, which resulted in 
185 CpG probes (44%). It should be noted that the majority of methylation of CpG probes were 
within an accurate range showing a strong relationship with the respective gene expression. The 
selected the 185 CpG probes corresponds to 159 genes that: 111 has CpG sites with single 
localization belong to the specific pattern for breast cancer. The top 20 most significant CpG 
probes are represented in Table 4.8. 
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Table  4.8 – Top 20 of most significant CpG probes selected for liver cancer based on the MLR 
analysis. 
cg Gene Localization Delta-beta p-value 
cg10479063 PZP 1stExon 0.217808 2.77E-57 
cg19358195 RPS6KA6 TSS1500 0.299307 7.74E-28 
cg15452017 COX7B2 5'UTR -0.2069 2.80E-25 
cg02215603 HHIP Body -0.32207 3.73E-24 
cg00012148 TINAG TSS1500 -0.26392 8.24E-22 
cg25368212 SSX1 TSS1500 -0.20673 3.17E-20 
cg13510648 VCX3A 5'UTR -0.42249 7.64E-19 
cg20683151 TM4SF20 1stExon -0.2109 1.04E-17 
cg07041214 OR56A3 1stExon -0.36219 2.29E-17 
cg00974523 PRDM7 3'UTR -0.26688 6.14E-17 
cg09771429 LDLRAD1 TSS200 -0.26845 4.48E-16 
cg25451456 OR56A3 TSS1500 -0.28525 5.79E-16 
cg11357940 ZNF716 Body -0.34037 1.17E-15 
cg22467052 CFTR Body -0.2979 3.34E-15 
cg17616453 C21orf62 5'UTR -0.2414 3.21E-14 
cg21860285 CPA6 TSS1500 -0.2323 2.16E-13 
cg05626117 CLEC4G TSS1500 -0.27335 9.50E-13 
cg22165105 TINAG 3'UTR -0.25925 1.11E-12 
cg06563300 SLC17A8 TSS200 0.209888 1.13E-12 
cg22799510 PROK2 3'UTR -0.25783 1.32E-12 
 
 
 
 Lung cancer has 210 significant CpG probes that are distributed throughout gene 
considering only the probes with a single localization as followed: 27% TSS1500, 17% 
TSS200, 8% 5UTR, 2% 1st exon, 39% body and 4% 3'UTR. Assuming more demanding 
criteria related to p-values we considered, in this context, p-values<0.0005, since the gene 
expression and methylation are “deep variables” (have many decimals), which resulted in 120 
CpG probes (57%). It should be noted that the majority of methylation of CpG probes were 
within an accurate range showing a strong relationship with the respective gene expression. The 
selected the 120 CpG probes corresponds to 86 genes that: 44 has CpG sites with single 
localization belong to the specific pattern for lung cancer. The top 20 most significant CpG 
probes are represented in Table 4.9. 
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Table  4.9 – Top 20 of most significant CpG probes selected for lung cancer based on the MLR 
analysis. 
cg Gene Localization Delta-beta p-value 
cg01392518 T TSS1500 0.218394 6.42E-15 
cg18768582 HBG1 Body -0.22737 1.61E-14 
cg12559170 HBG2 Body -0.23612 9.96E-14 
cg24748769 OTX2 Body 0.280923 8.20E-12 
cg16856286 HOXC13 1stExon 0.270299 1.12E-11 
cg11781718 HIST1H4E TSS1500 0.237443 1.54E-11 
cg06463958 T TSS1500 0.288948 3.18E-11 
cg07854132 OVCH1 TSS200 -0.29594 5.78E-11 
cg19924352 FAM83A 1stExon -0.28377 8.79E-11 
cg23507945 IL22RA2 Body -0.27795 1.06E-10 
cg13791254 FOXE1 1stExon 0.297016 1.55E-10 
cg01708273 HOXD11 3'UTR 0.363357 2.70E-10 
cg16413687 ALX1 TSS1500 0.208811 3.67E-10 
cg00633740 EDN3 Body -0.20982 1.94E-09 
cg26336935 KRT16 TSS200 -0.21271 4.47E-09 
cg02650767 OR2B11 1stExon -0.26845 1.09E-08 
cg16464328 SLC4A1 TSS1500 -0.20833 1.20E-08 
cg18451814 OTX2 TSS1500 0.327475 2.22E-08 
cg19134945 PITX2 TSS200 0.236844 4.25E-08 
cg06404175 OXT Body 0.251856 4.37E-08 
 
 
 
 
 Thyroid cancer has 31 significant CpG probes that are distributed throughout gene 
considering only the probes with a single localization as followed: 27% TSS1500, 17% 
TSS200, 8% 5UTR, 2% 1st exon, 39% body and 4% 3'UTR. Assuming more demanding 
criteria related to p-values we considered, in this context, p-values<0.0005, which resulted in 
27 CpG probes (87%). It should be noted that the majority of methylation of CpG probes were 
within an accurate range showing a strong relationship with the respective gene expression. The 
selected the 27 CpG probes corresponds to 23 genes that: 17 has CpG sites with single 
localization belong to the specific pattern for thyroid cancer. The 17 most significant are 
represented in Table 4.10. 
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Table  4.10 – Top 17 of most significant CpG probes selected for thyroid cancer based on the MLR 
analysis. 
cg Gene Localization Delta-beta p-value 
cg23620049 LIPH TSS200 -0.3957 2.02E-80 
cg08328750 KRT15 TSS200 -0.30161 5.28E-68 
cg12403889 C1orf187 5'UTR -0.29036 7.35E-44 
cg03255783 ESPN Body -0.20309 1.19E-38 
cg01802532 NMU Body -0.22039 6.36E-37 
cg04473405 KRT85 TSS1500 -0.30272 1.06E-28 
cg25959149 BANF2 TSS200 0.248938 7.48E-24 
cg22717825 PLA2G2E TSS200 -0.36306 2.77E-16 
cg03448202 MYBPH TSS200 -0.33929 2.95E-16 
cg15442792 MUC21 TSS200 -0.35681 5.90E-14 
cg20695587 TMPRSS11F TSS200 -0.26451 1.48E-11 
cg25388882 C1orf180 Body -0.34318 1.69E-07 
cg19856444 SLC39A12 5'UTR -0.26777 1.54E-05 
cg02196805 CSF2 1stExon -0.30557 5.18E-05 
cg18959422 MYBPH TSS1500 -0.22881 5.21E-05 
cg18122696 SYT8 TSS1500 -0.3032 0.000195 
cg23904115 AWAT2 TSS1500 -0.28298 0.000263 
 
 
 This significant CpG probes were majority located in genes that were specific for each 
type of cancer. This fact reveals that these specific patterns suggest high relevance in the initial 
distinction of the tumorigenesis, since the transcription start sites, 1500 and 200, were even 
more important after these results, making them preferred methylation sites soon after the gene 
body. 
 
 
 
4.5.3. cDMGs using multivariate approach – Phase 5 
 Multivariate HJ-biplot technique was applied to all cohorts for the gene expression and 
DNA methylation. This procedure aimed to evaluate samples distribution, through the most 
important genes or CpG probes, in order to observe if effectively the solid tissue normal and 
stage I primary tumor samples were delimited in the same distribution space (Appendix 9). This 
multivariate data reduction approach also helped to corroborate the designed pipeline.  
 In breast cancer, HJ-biplot for gene expression were represented in Figure 4.7. Results 
show that KCNJ16, HPSE2, LRRC3B, DPP6 and CPA1 were genes with high importance in 
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the distribution of samples, when we consider their vector norm. We also verified that HPSE2-
LRRC3B and DPP6-CPA1 were strongly correlated. Colors of HJ-Biplot coordinates represent 
the output of hierarchical clustering procedure, which was discriminated in three groups 
characterized by: C1 with 80 normal samples, C2 with 4 normal and 29 tumor samples and C3 
with 97 tumor samples. Additionally, results showed that C1 group is well differentiated and 
positioned in the same direction of genes and in opposition to C3. This fact suggests that higher 
levels of gene expression in normal samples have lower gene expression levels in tumor 
samples, considering the genes: KCNJ16, HPSE2, LRRC3B, DPP6 and CPA1. Indeed, the 
log2(Foldchange) of that set of genes (-1.56, -1.79, -1.98, -1.71 and -2.41, respectively) 
confirmed this tendency of down-regulation of gene expression. However, there is an 
intermediate cluster, C2, where samples are also closer to the other clusters, meaning that those 
samples might be confused. This HJ-Biplot representation retains 85.7% of variance in the plan 
1-2 (Figure 4.7). Importantly, in the HJ-Biplot representation, we recognized one gene (CPA1) 
which have been previously described in a specific pattern for breast cancer. Interestingly, that 
gene presents the lower log2(Foldchange). 
 Moreover, DNA methylation HJ-Biplot (Annex 1) is similar to the gene expression HJ-
Biplot. Clusters are distributed by: C1 with 84 normal and 14 tumor samples, C2 with 75 tumor 
samples and C3 with 37 tumor samples. C2 cluster is an intermediate group doubtful in terms 
of effective classification of normal or tumor. C1 is essentially explained by the high variability 
in 14 CpG probes which are in the same samples direction. However, tumor samples were 
influenced by other 5 CpG probes. Interestingly, a more detailed analysis revealed that 19 CpG 
probes belong to only two of the referred genes. DPP6 presents 16 CpG probes (5 
hypermethylated and 11 hypomethylated) according to the previously verified in the graph. At 
last, the 4 CpG probes remaining (4 hypomethylated) are located in the KCNJ16 gene. This 
suggests that DPP6 gene is very important in breast cancer, although it is not specific. DNA 
methylation HJ-Biplot retained 88% of variance in the plan 1-2. 
 In breast cancer, in spite of the working pipeline performed, there is yet an intermediate 
group (for gene expression and methylation) in terms of centroids distance related to the normal 
exclusive (C1) group and the tumor exclusive samples, cluster C3. This fact reveals that remains 
a kind of a “doubt group” to take into account, since it does not distance itself sufficiently from 
the other clusters and, eventually, it can signify misrepresented or classified samples. 
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 In colorectal cancer, HJ-Biplot for gene expression is represented in Figure 4.8. Results 
identified a set of 84 genes with impact in the distribution of samples. All of them are positively 
correlated. Cluster analysis reveals three well defined groups: C1 with 21 normal samples, C2 
with 18 tumor samples and C3 with 36 tumor samples. Samples in C1 were distributed through 
influence of genes. Indeed, these genes are all down-regulated in tumor samples. TMEFF2 gene 
presents the biggest difference (log2(Foldchange) = -3.81). Other clusters are further away from 
C1 and without samples intersections. Gene expression HJ-Biplot retains 86.4% of the variance 
in the plan 1-2. Looking at specific gene pattern for each type of cancer, from third aim, we 
verified that 61 genes are specific for colorectal cancer, being TMEFF2 one example of them.  
Figure 4.7 – HJ-biplot for gene expression in breast cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 85.7% of variance.  Hierarchical 
clusters are represented in red (C1), green (C2) and blue (C3). C1 with 80 normal, C2 with 4 normal 
and 29 tumor samples and C3 with 97 tumor samples. 
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 DNA methylation HJ-Biplot had a similar behavior to gene distribution (Annex 2). 
From clustering, results in three clusters, C1 with 21 normal and 2 tumor samples, C2 with 25 
tumor samples and C3 with 27 tumor samples. C1 was essentially explained by 14 CpG probes 
and C3 by 102 CpG probes, in opposite side. Interestingly, the same behavior was verified 
through the Δβ. Specifically, TMEFF2 presents 5 hypermethylated CpG probes, suggesting a 
high control of gene expression. DNA methylation HJ-Biplot retained 85.3% of the variance in 
the plan 1-2. 
 In colorectal cancer, were found three well defined clusters. One of them corresponds 
to normal samples and the other two are tumor groups. Moreover, the group constituted by 
normal samples are sufficiently distant from tumor groups, suggesting a strong possibility that 
they might have subgroups in stage I tumor samples. 
 
Figure 4.8 – HJ-biplot for gene expression in colorectal cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 86.4% of variance. Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 21 normal samples, C2 with 18 tumor 
samples and C3 with 36 tumor samples. 
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 In head and neck cancer, HJ-biplot for gene expression is represented in the Figure 4.9. 
Results showed that there was a set of 7 genes with impact in the distribution of samples, and 
the hierarchical clusters analysis was distributed: C1 with 16 normal samples, C2 with 3 normal 
and 8 tumor samples and C3 with 1 normal and 19 tumor samples. Additionally, the group 
constituted only by normal samples (C1) was well differentiated and positioned in the same 
orientation of genes. Indeed, all genes were down-regulated in tumor samples according to the 
working pipeline. Furthermore, exists an intermediate group (C2) that translates doubt in terms 
of effective classification of samples. Gene expression HJ-Biplot retained 87.1% of the variance 
in the plan 1-2. Looking at the specific pattern of genes for each type of cancer from third aim, 
we verified that 5 genes are specific for head and neck cancer. FOXI2 and GRIK3 genes are 
examples of this with a log2(Foldchange) = -1.97 and -1.61, respectively. 
 However, the behavior of DNA methylation HJ-biplot is similar to the distribution in 
gene expression (Annex 3). From clustering, results three clusters (C1 with 19 normal and 1 
tumor samples, C2 with 6 tumor samples and C3 with 1 normal and 20 tumor samples), C3 
essentially explained by the variability power of the following 7 CpG probes. Interestingly, all 
CpG probes are hypermethylated and were located in FOXI2 (5 CpG probes) and GRIK3 (2 
CpG probes). Importantly, C1 is very cohesive and defined. Additionally, it should also be 
noted that there is an intermediate cluster (C2) great defined with more variability that each 
other.  DNA methylation analysis in head and neck cancer gives us a quantification of 
information from the 1-2 plans in the order of 95.8%. 
 In Head and neck cancer, three bordered clusters were found. One of them corresponds 
to the normal samples and two tumor groups sufficiently distant between them. However, since 
there are blue samples closer to C1 is doubtful to suggest that the C2 is well defined. 
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 In kidneyR cancer, HJ-biplot gene expression is represented in Figure 4.10. Results 
showed that there are 2 sets of important genes in samples distribution: 44 genes with the 
principal impact on normal samples (left side) and 3 genes in the distribution of tumor samples 
(left right). Hierarchical clusters analysis is distributed: C1 with 24 normal samples, C2 with 
41 tumor samples and C3 with 144 tumor samples. Indeed, this behavior agreed with working 
pipeline results (44 genes down-regulated and 3 genes up-regulated). Although well bordered 
clusters, C2 has samples closer to C1 and C3. Gene expression HJ-Biplot retained 85.9% of the 
variance in the plan 1-2. When we looked at the specific pattern of genes for each type of cancer 
from second objective, we verified that 27 genes have a specific gene for kidneyR cancer. 
RANBP3L gene, a downregulated gene (log2(Foldchange) = -1.83), is an example of them. 
           DNA methylation HJ-biplot was different in to samples distribution (Annex 4). 
Clustering results showed: C1 with 21 normal and 12 tumor samples, C2 with 3 normal and 74 
Figure 4.9 – HJ-biplot for gene expression in head and neck cancer. This representation results from 
a variable selection with more than 70% of contribution, retaining 87.1% of variance. Hierarchical 
clusters are represented in red (C1), blue (C2) and green (C3). C1 with 16 normal, C2 with 3 normal 
and 8 tumor samples and C3 with 1 normal and 19 tumor samples. 
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tumor samples and C3 with 69 tumor samples. C2 and C3 are merged and directly correlated 
with 25 hypermethylated CpG probes according to the results obtained by the working pipeline. 
DNA methylation HJ-Biplot retains 88.8% of the variance in the plan 1-2. 
            In kidneyR cancer, seems that gene expression has more influence in differentiating 
samples, when compared to DNA methylation. In fact, clusters obtained by DNA methylation 
were undefined if we consider the intersections of samples. 
 
  
 In KidneyP cancer, HJ-biplot for gene expression is represented in Figure 4.11. Results 
showed that there are 19 genes with impact in the samples distribution. Hierarchical clusters 
analysis is distributed: C1 with 23 normal and 4 tumor samples, C2 with 105 tumor samples 
and C3 with 58 tumor samples and verified that C2 and C3 overlapping. Genes are distributed 
Figure 4.10 – HJ-biplot for gene expression in kidneyR cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 85.9% of variance. Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 24 normal, C2 with 41 tumor samples 
and C3 with 144 tumor samples. 
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according to normal samples and confirmed by working pipeline. Indeed, all of them are down-
regulated in tumor. Gene expression HJ-Biplot retained 87.5% of the variance in the plan 1-2. 
Looking at the specific pattern of genes for each type of cancer from second objective, we 
verified that 10 genes are specific for kidneyP cancer. SLC4A9 is an example of a specific down-
regulated gene for each cancer (log2(Foldchange) = -1.83). 
           DNA methylation HJ-biplot is similar to the gene expression distribution (Annex 5). 
Clustering results are distributed: C1 with 23 normal and 11 tumor samples, C2 with 63 tumor 
samples and C3 with 93 tumor samples, also considering that C2 and C3 are overlapped and 
explained by 7 CpG probes. Confirmed by the working pipeline as hypermethylated CpG probe. 
DNA methylation HJ-Biplot retained 89.9% of the variance in the plan 1-2. 
           In kidneyP cancer, it was observed that in gene expression are not necessarily three 
clusters, since two of them are almost total overlapped. Same patterns were seen in the DNA 
methylation HJ-Biplot (Annex 5). This fact strongly suggests that we have truly two groups of 
samples. However, once the distribution of C1 samples was 32% for tumor and 68% for normal 
samples, since with substantial distance between C1 and C2-C3, the C1 must have further 
attention to answer why those tumor samples were in there. In summary, in this type of cancer 
is not clear that we can properly differentiate tumor from normal samples. 
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 In liver cancer, HJ-biplot for gene expression is represented in Figure 4.12. Results 
showed that 13 genes have an impact in samples distribution. Interestingly, all genes are down-
regulated with conferring of previous results of working pipeline. Hierarchical clusters are 
distributed: C1 with 40 normal and 6 tumor samples, C2 with 1 normal and 20 tumor samples 
and C3 with 145 tumor samples were C2 - C3 overlapping. These genes follow the same 
behavior of the previous cohort. All genes are down-regulated and confirmed the HJ-Biplot 
tendency. Looking at the specific gene pattern for each type of cancer from second objective, 
we verified that 11 genes are for liver cancer.  
 DNA methylation HJ-biplot was similar to the gene expression distribution (Annex 6). 
Clustering results are distributed: C1 with 41 normal and 70 tumor samples, C2 with 49 tumor 
samples and C3 with 52 tumor samples. CpG probes are in the same direction as C1, contrary 
Figure 4.11 – HJ-biplot for gene expression in kidneyP cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 87.5% of variance.  Hierarchical 
clusters are represented in red (C1), blue (C2) and green (C3). C1 with 23 normal and 4 tumor samples, 
C2 with 105 tumor samples and C3 with 58 tumor samples. 
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to the other cohorts. Tumor patients of this cluster suggests a high proximity with normal 
samples. All CpG probes are Hypo-methylated in tumor confirmed by working pipeline.  DNA 
methylation HJ-Biplot retained 81.9% of the variance in the plan 1-2. 
 In liver cancer, three clusters are defined, but the C1 presents a mix of samples 
suggesting a high proximity between normal samples and subgroup of tumor samples. Other 
clusters are well defined. Importantly, liver cancer presents hypomethylated CpG probes and 
down-regulated respective genes with more importance to differentiate groups.  
 
 
 
 
 
Figure 4.12 – HJ-biplot for gene expression in liver cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 93% of variance. Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 40 normal and 6 tumor samples, C2 with 
1 normal and 20 tumor samples and C3 with 145 tumor samples. 
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 In lung cancer, HJ-biplot for gene expression is represented in Figure 4.13. Results 
identified 7 genes with impact in samples distribution. Hierarchical clusters are distributed: C1 
with 21 normal and 19 tumor samples, C2 with 149 tumor samples and C3 with 77 tumor 
samples. Indeed, all genes are down-regulated according to working pipeline analysis. Results 
showed that C1 was constituted by approximately 50% of tumor samples, and other clusters are 
overlapped. This fact means that it was difficult to differentiate clusters of samples in this cancer 
type. Gene expression HJ-Biplot retained 79.5% of the variance in the plan 1-2. 
Looking at the specific pattern of genes for each type of cancer from second objective, we 
verified that only 2 genes (AGBL1 and OVCH1) are specific for lung cancer, but do not have 
selected CpG probes. 
 DNA methylation HJ-biplot is similar to gene expression distribution (Annex 7). 
Clustering results are distributed: C1 with 21 normal and 24 tumor samples, C2 with 135 tumor 
samples and C3 with 86 tumor samples. Same behavior of hypermethylation was verified. DNA 
methylation HJ-Biplot retained 81.5% of the variance in the plan 1-2. 
 In liver cancer, C1 presents a merge of normal and tumor samples suggesting a high 
proximity. C2-C3 are merged forming only a cluster. In contrast, DNA methylation 
approximates samples of C1, expanding samples from C2 and C3. This fact suggests that 
methylation has more explicability in normal samples. 
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 In thyroid cancer, HJ-biplot for gene expression is represented in Figure 4.14. Results 
showed that there are 6 genes which have an impact in samples distribution. Hierarchical 
clusters are distributed: C1 with 49 normal and 59 tumor samples, C2 with 1 normal and 97 
tumor samples and C3 with 128 tumor samples. Results showed one group with tumor samples 
(C3) and two merged groups (C1-C2) with both tumor and normal samples. Genes are in the 
same direction of tumor groups revealing be up-regulated according to the results obtained by 
the working pipeline. Gene expression HJ-Biplot retained 88.1% of the variance in the plan 1-
2. Looking at patterns of specific genes for each type of cancer from second objective, we 
verified that only 6 genes have a specific gene for thyroid cancer. MUC21 is an example of 
them, presetting log2(Foldchange) = 2.26. 
Figure 4.13 – HJ-biplot for gene expression in lung cancer. This representation results from a variable 
selection with more than 70% of contribution, retaining 79.5% of variance. Hierarchical clusters are 
represented in red (C1), blue (C2) and green (C3). C1 with 21 normal and 19 tumor samples, C2 with 
149 tumor samples and C3 with 77 tumor samples. 
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           DNA methylation HJ-biplot was similar to the gene expression distribution. (Annex 8). 
Clustering results are distributed: C1 with 50 normal and 76 tumor samples, C2 with 77 tumor 
samples and C3 with 131 tumor samples. C3 is directly correlated with 25 hypomethylated   
CpG probes according to the results of the working pipeline. DNA methylation HJ-Biplot 
retained 88.1% of the variance in the plan 1-2. 
  In thyroid cancer, samples present high proximity. C1 is composed by a merge of normal 
and tumor samples, revealing few differences. C2 is an intermediary group that merged with 
C3 and C1. Contrary, DNA methylation presents more differences between groups distributed 
them more defined. 
 
 
 
Figure 4.14 – HJ-biplot for gene expression in thyroid cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 88.1% of variance. Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 49 normal and 59 tumor samples, C2 
with 1 normal and 97 tumor samples and C3 with 128 tumor samples. 
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5 CHAPTER 5 – DISCUSSION 
 In this study, we developed a mathematical structured model to explore big data 
resources through the design of a Working Pipeline (WP).  
 An exponential increase in data repositories is being observed. TCGA is a good example 
of public platforms and was the resource of gene expression and DNA methylation of this study. 
We analyzed 20502 genes and 364643 CpG probes as our initial variables in order to compare 
normal tissue and stage I primary tumor groups.   
 Here, we developed a tool that pretends to identify specific patters across cancers. For 
that, we stratified our model into 6 different Phases distributed into two components: 4 phases 
in principal component and 2 phases in complementary component. 
 Firstly, to characterize descriptively the data information is essential to be aware of the 
main studied populations features (Figure 4.1: Phase 0).  
 Then, to organize the data is essential to prepare inputs in order to be used in the next 
phase. Performing tests to compare two general groups is crucial to sustain the effective 
difference in those subsets and apply strategic cut points is necessary to improve general 
accuracy (Figure 4.1: Phase 1).  
 After, the development of strategies to analyze intersections of variables is also 
necessary to identify patterns to characterize cancer populations (Figure 4.1: Phase 2).  
 Furthermore, identifying good predictors in order to discriminate groups is a 
fundamental procedure in cancer diagnosis (Figure 4.1: Phase 3).  
 Finally, it is important to perform other deep analysis such as: select variables that have 
a truly impact in other variables, such as which CpG probes were significant in the dynamics 
of gene expression (Figure 4.1: Phase 4); and to perform graphic representations to visualize 
latent correlations, between gene expression and DNA methylation, that only multivariate 
approaches can capture (Figure 4.1: Phase 5). 
 Next, we tested our developed model in 8 TCGA cohorts.  
 In this WP, the pre-processing data and the variables selection were performed in the 
Phase 1, saved in Output 1 and matched with the same criteria as founded in  Zhang et al. 2015 
study. We also included an outlier procedure (Boxplot method) to remove discrepant data, since 
we had substantial differences in sample sizes. 
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 Moreover, in Phase 1 we performed a t-test to differentiate the mean of gene expression 
levels in normal and tumor samples. Also, the Pearson test was used to identify significant 
correlations between patterns of gene expression and differentially methylated CpG probes and 
saved in Output 3. These statistical procedures were also performed in the previously 
mentioned study (Zhang et al. 2015). 
 In order to cover all the tests in accordance to statistical assumptions, we also performed, 
in Phase 1, the non-parametric Wilcoxon test (Mann-Whitney U test) for unpaired samples to 
compare methylation and gene expression mean levels (normal vs tumor), depending on the 
Shapiro-Wilk normality test results. The methylation cutoff was |Δβ| > 0.2 and the considered 
gene expression cutoff was |Foldchange| > 2.8. This was also done in another study (Wei et al. 
2016) although the gene expression cutoff was different (|Foldchange| > 2) (Output 2). 
 In Phase 2, we computed an intersection function that combined set of genes or CpG 
probes across all cancer cohorts. This phase reported to Output 4 the frequency of all 
intersections of genes. 
 In Phase 3, we performed ROC curve analysis to identify potential new biomarkers for 
our cancer cohorts (Output 5). Also, this diagnostic tool was used previously to  identify 
potential new biomarkers in rectal cancer (Wei et al. 2016). 
 Next, in Phase 4, linear regression models were performed to capture the significant 
CpG probes in the variation of gene expression. We predefined the top 20 of more significant 
CpG probes in gene expression (Output 6). 
 Finally, in Phase 5, we used the HJ-Biplot representation to assess sample distributions 
according to the multivariate behavior of genes and CpG probes. Aberrant methylation 
changes can start very early in tumor development promoting several signaling pathways 
abnormalities, such as genetic and epigenetic instability (Baylin et al. 2001). Therefore, 
identifying cDMGs for each cancer type is of most relevance. 
 Aberrant methylation changes can start very early in tumor development, mediate a 
several important signaling pathways abnormalities in cancer, such as genetics instability. 
Identifying cDMGs is very appellative reason for the main hypothesize if all types of cancer 
have the same dynamic changes.  
 Since tumorigenesis involves a lot of aberrant alterations (Hanahan et al. 2000) it was 
expected that a large sets of genes and CpG probes were altered between normal and stage I 
tissue from different tumors. For each tumor type, a coverage of 20531 genes and 48557 CpG 
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probes is provided at TCGA data sets. (Figure 4.2A). Upon applying our Phase 1 step we 
verified that a small set of genes (25 in thyroid cancer and 349 in liver cancer) and CpG probes 
(40 in thyroid cancer and 1453 in liver cancer) characterized cancer initiation (Figure 4.2C).  
 Also, our data showed that liver and colorectal cancer presents the most changes in gene 
expression and DNA methylation (Figure 4.2C). Both organs are directly linked to metabolism 
and they are constant contact with many insults. Previous studies revealed that lesions caused 
by inflammation, mechanical and chemical agents promote a chronic immune response that 
potentiates cell proliferation and regeneration (Mariani et al. 2014). Also, high risk of cancer is 
associated to life habits, such as: tobacco, diet, obesity, alcohol, among others (Simon 2016). 
In contrast, thyroid cancer showed to be the cancer with less epigenetic alterations, suggesting 
a slower development. Interestingly this tumor type is often indolent and is considered a curable 
cancer when diagnosed at early stages (Mazzaferri & Kloos 2001). 
 We also verified that there are cohorts defined by specific gene expression profiles. In 
deed breast, liver, lung and thyroid cancers present more upregulated genes suggesting a 
positive transcription regulation. In contrast, colorectal, head and neck, kidneyR and kidneyP 
cancers presents more downregulated genes revealing a negative transcription regulation. It is 
interesting to notice that the downregulated cancer cohorts were more associated to 
hypermethylated CpG probes where the upregulated cohorts were associated to hypomethylated 
CpG probes. This fact suggests that overall hypermethylation is associated to downregulation 
and hypomethylation to upregulation (Victoria Valinluck Lao and William M. Grady 2011). 
However, some tumor types including liver and breast cancer showed hypermethylation to be 
associated to upregulation. Previous studies have already reported this trend (Castelo-Branco 
et al. 2013; Bert et al. 2013).  
 This study identified, for each cohort, multiple CpG sites differentially methylated 
which are correlated to alterations in gene expression (Figure 4.3). We verified that most 
altered CpG sites were located in transcription start sites (TSS1500, TSS200) and in the gene 
body in agreement with other previous studies (Kumar Mishra & Guda 2017).  
 Interestingly, CpG presenting an hypomethylated status were mostly located in the gene 
body where hypermethylated CpGs were mostly at transcription starts site. This is consistent 
with the dogma where of cancer epigenetics where it is observed global hypomethylation and 
specific hypermethylation.  
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 Biological process enrichment analysis was based on a gene ontology platform (Figure 
4.4). Our results showed that events associated to the nervous system and development were 
enriched in all cohorts. Interestingly, chemical synaptic transmission was also presented in the 
majority of the analyzed cohorts.  
 Next, we performed literature searches and observed that approximately 87% of cancer 
differentially methylated genes that came out in our analysis were previously reported in cancer. 
(Figure 4.5). Strikingly, more than 10% of the genes identified by our model have not yet been 
reported in cancer and can therefore be potential cancer biomarkers. 
 Analysis of patterns across the different cancer cohorts revealed that the majority of the 
cDMGs are tissue-specific for early stages of the disease (Output 4), suggesting that regulation 
of these key genes depends on the cell where it originates (Figure 4.6). In fact, genome-wide 
DNA methylation profiling study identified differentially methylated regions in 17 human 
somatic tissues which are also tissue-specific (Lokk et al. 2016).. However, more genome-wide 
multicenter studies are necessary to validate this hypothesis. 
 Next, we did pathways enrichment analysis in a Reactome Pathway Database. 
Regarding colorectal cancer, RAF/MAP kinase cascade that is involved in the regulation of cell 
proliferation, differentiation, migration and apoptosis was enriched in our study. (Slattery et al. 
2012). In head and neck cancer, the GABA A receptor activation is an enriched pathway that 
plays a role in the vertebrate central nervous system (Simon et al. 2004). Importantly, in the 
present study, this pathway related to the nervous system was found to be enriched. In lung 
cancer OPRD1(log2(foldchange)=4.29) is an example of a gene that is upregulated and part of 
the peptide ligand-biding receptors pathway. Interestingly, this gene was found to be 
overexpressed in lung cancer  but not in normal lung (Cohen et al. 2016). In kidneyP cancer the 
ion homeostasis pathway was found to be enriched and previous studies reported this 
mechanisms to be downregulated in kidney tumor cells (Boer et al. 2001). At last, adherent 
junction interactions is an enriched pathway in liver cancer.  
 We then searched for biomarkers with diagnostic potential and identified a subset of 
cDMGs for each cohort (Output 5). Good potential new biomarkers were discriminated to select 
the tissue-specific pattern of cDMGs. As examples we saw that in breast cancer out of the 19 
specific cDMGs which were considered as good diagnostic predictors, 5 have never been 
mentioned in cancer, such as METTL11B (AUC = 0.83) with cg20742415 (AUC = 0.83). 
METTL11B or NRMT2 (N-terminal RCC1 methyltransferase) is a methyltransferase primarily 
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monomethylase to specifically methylate free α-amino group of proteins (Petkowski et al. 
2013). In colorectal cancer, from a set of 153 specific genes, 64 have not yet been reported in 
cancer, such as RIC3 (AUC=0.97) which presents the cg04886703 (AUC=0.99) as also a good 
diagnostic biomarker. Interestingly, this gene was reported to promote  the expression of the 
nicotinic acetylcholine receptor alpha7 subunit (Halevi et al. 2003). In the complementary phase 
(Phase 4), we attested the significant methylation of CpG probes that contributes to the dynamic 
performance of gene expression. Regarding to the top of the most significant CpG probes, we 
found that, in all cancer cohorts, the region of the transcription start sites is more enriched, 
followed by gene body. In fact, cg20742415 (p-value=1.99e-10) in breast cancer was located 
in TSS1500 and cg03827337 (p-value=0.028) in head and neck. However, cg18390495 (p-
value=3.76e-44) in kidneyR cancer, as well as, cg20685897 (p-value=7.67e-05) in liver cancer 
were located in the gene body. Interestingly, gene body methylation has been reported as a 
potential therapeutic target for modulation of transcription levels (Yang et al 2018).  
 Finally, in order to validate the developed WP, we used HJ-Biplot for all cancer cohorts 
analyzed and observed that when genes or CpG probes were projected in the direction of normal 
samples, they were downregulated or hypomethylated, respectively. Indeed, these genes and 
CpG probes explained the distribution of normal samples. In opposition, when genes or CpG 
probes were projected in the direction of tumor samples, they were upregulated or 
hypermethylated, respectively. Additionally, since this analysis was performed based on normal 
samples these results were in agreement with the principal component of the WP that can be 
used in other scientific contexts. 
 
5.1. Limitations of study 
This present study presents some limitations, such as: 
1. Number of samples varied among the different cohorts, which may contribute to a 
decrease robustness of our analyzes; 
2. Normal patient samples were not obtained from normal patients, but rather extracted 
from tumor adjacent tissue of patients with disease. As these surrounding tissues may already 
experience some alterations this can affect the viability of our results. 
3. These results were not validated by another data sets. 
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6 CHAPTER 6 – CONCLUSION 
 We develop a novel working pipeline that permits analyzing big data sets available 
worldwide. For that we used a mathematical structured model that imports, exports, cleans and 
computes statistical power techniques for big data repositories.  
 In order to validate our model, we use TCGA data on multiple tumor types. 
 Remarkably, our findings evidence that the transition between normal tissue into a 
carcinogenic stage is not a conserved event that occurs in different tumor types but specific to 
the cell of origin. 
 Indeed, specific patterns of gene expression and differentially methylated genes allowed 
to find new biomarkers with high capacity to discriminate normal and tumor samples in the 
initial stages of cancer. 
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ANNEXES 
 
 
 
 
 
 
 
 
 
 
 
Annex 1 - HJ-biplot for DNA methylation in breast cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 88% of variance.  Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 84 normal and 14 tumor samples, C2 
with 75 tumor samples and C3 with 37 tumor samples. 
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Annex 2 – HJ-biplot for DNA methylation in colorectal cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 85.3% of variance. Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 21 normal and 2 tumor samples, C2 with 
25 tumor samples and C3 with 27 tumor samples. 
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Annex 3 – HJ-biplot for DNA methylation in head and neck cancer. This representation results from 
a variable selection with more than 70% of contribution, retaining 95.8% of variance. Hierarchical 
clusters are represented in red (C1), blue (C2) and green (C3). C1 with 19 normal and 1 tumor samples, 
C2 with 6 tumor samples and C3 with 1 normal and 20 tumor samples. 
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Annex 4 – HJ-biplot for DNA methylation in kidneyR cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 88.8% of variance. Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 21 normal and 12 tumor samples, C2 
with 3 normal and 74 tumor samples and C3 with 69 tumor samples. 
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Annex 5 – HJ-biplot for DNA methylation in kidneyP cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 89.9% of variance. Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 23 normal and 11 tumor samples, C2 
with 63 tumor samples and C3 with 93 tumor samples. 
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Annex 6 – HJ-biplot for DNA methylation in liver cancer. This representation results from a variable 
selection with more than 70% of contribution, retaining 81.9% of variance. Hierarchical clusters are 
represented in red (C1), green (C2) and blue (C3). C1 with 41 normal and 70 tumor samples, C2 with 
49 tumor samples and C3 with 52 tumor samples. 
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Annex 7 – HJ-biplot for DNA methylation in lung cancer. This representation results from a variable 
selection with more than 70% of contribution, retaining 81.5% of variance. Hierarchical clusters are 
represented in red (C1), blue (C2) and green (C3). C1 with 21 normal and 24 tumor samples, C2 with 
135 tumor samples and C3 with 86 tumor samples. 
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Annex 8 – HJ-biplot for DNA methylation in thyroid cancer. This representation results from a 
variable selection with more than 70% of contribution, retaining 88.2% of variance. Hierarchical clusters 
are represented in red (C1), green (C2) and blue (C3). C1 with 50 normal and 76 tumor samples, C2 
with 77 tumor samples and C3 with 131 tumor samples. 
